Human adult olfactory neural progenitors	1
axotomized rubrospinal tract axonal reinnervation and locomotor recovery Ming Xiao , a , Kathleen M. Klueber , b JianPing Zhou , a , b Zhanfang Guo , a Chengliang Lu , a Heming Wang , a and Fred J. Roisenb	50
axotomized rubrospinal tract axonal reinnervation	50
axotomized rubrospinal tract	50
axonal reinnervation	79
locomotor recovery Ming Xiao , a , Kathleen M. Klueber , b JianPing Zhou , a , b Zhanfang Guo , a Chengliang Lu , a Heming Wang , a and Fred J. Roisenb	104
locomotor recovery Ming Xiao	104
a	134
Kathleen M. Klueber	138
b JianPing Zhou	158
a	174
b Zhanfang Guo	176
a Chengliang Lu	191
a Heming Wang	207
a	221
Fred J. Roisenb	227
We	246
the effects of engrafted human adult olfactory neuroepithelial neurosphere forming cells -LRB- NSFCs -RRB- on regeneration and reinnervation of rubrospinal tract -LRB- RST -RRB- axons and locomotor recovery following partial cervical hemisection that completely ablated the RST	262
the effects	262
human adult olfactory neuroepithelial neurosphere	287
cells -LRB- NSFCs -RRB- on regeneration and reinnervation of rubrospinal tract -LRB- RST -RRB- axons and locomotor recovery following partial cervical hemisection that completely ablated the RST	345
cells	345
NSFCs	352
regeneration and reinnervation of rubrospinal tract -LRB- RST -RRB- axons and locomotor recovery following partial cervical hemisection that completely ablated the RST	362
regeneration and reinnervation of rubrospinal tract -LRB- RST -RRB- axons	362
regeneration and reinnervation	362
rubrospinal tract -LRB- RST -RRB- axons	396
locomotor recovery following partial cervical hemisection that completely ablated the RST	430
locomotor recovery	430
partial cervical hemisection that completely ablated the RST	459
partial cervical hemisection	459
the RST	512
Weekly behavioral testing	521
greater functional recovery of forelimb use	554
greater functional recovery	554
forelimb use	585
the 12 weeks	605
NSFCs engraftment	624
the control rats	650
Anterograde tracing with biotinylated dextran amine -LRB- BDA -RRB-	668
Anterograde	668
dextran amine -LRB- BDA -RRB-	706
dextran amine	706
BDA	721
the presence of RST axons	736
the presence	736
RST axons	752
the white matter 4 -- 8 segments caudal	769
the white matter 4	769
8 segments	788
the grafts	809
Both immunofluorescence and immunoelectron microscopy	821
the BDA-labeled RST axonal terminals reestablished synaptic connections with motoneurons in the ventral horn of the distal cervical spinal cord	884
the BDA-labeled RST	884
axonal terminals	904
synaptic connections	935
motoneurons	961
the ventral horn of the distal cervical spinal cord	976
the ventral horn	976
the distal cervical spinal cord	996
Further study of forelimb functional recovery in NSFCs-engrafted subgroups	1029
Further study	1029
forelimb functional recovery in NSFCs-engrafted subgroups	1046
forelimb functional recovery	1046
NSFCs-engrafted subgroups	1078
the effects of a second dorsolateral funiculotomy	1115
the effects	1115
a second dorsolateral funiculotomy	1130
the recovery , and the injection of muscimol	1190
the recovery	1190
the injection of muscimol	1208
the injection	1208
muscimol	1225
RST neuronal activity	1244
These results	1278
the unique potential of human olfactory neuroepithelial-derived progenitors as an autologous cell source for spinal cord repair	1302
the unique potential	1302
human olfactory neuroepithelial-derived progenitors as an autologous cell source for spinal cord repair	1326
human olfactory neuroepithelial-derived progenitors	1326
an autologous cell source for spinal cord repair	1381
an autologous cell source	1381
spinal cord repair	1411
Introduction The failure of axons to regenerate in the adult central nervous system -LRB- CNS -RRB-	1432
Introduction	1432
The failure of axons	1445
The failure	1445
axons	1460
the adult central nervous system	1483
CNS	1517
the intrinsic regenerative capacity of injured neurons as well as a nonpermissive environment -LRB- Beattie et al. , 1997 ; Geller and Fawcett , 2002 -RRB-	1545
the intrinsic regenerative capacity	1545
injured neurons as well as a nonpermissive environment	1584
injured neurons	1584
a nonpermissive environment	1611
Beattie	1640
et al. , 1997 ; Geller and Fawcett , 2002	1648
et al.	1648
1997 ; Geller and Fawcett	1656
1997	1656
Geller and Fawcett	1662
2002	1682
the past decade	1692
cellular replacement therapies	1709
exciting new therapeutic options	1752
regeneration	1796
several neurodegenerative or neurotrauma models	1812
example	1865
various cell types	1874
the rodent spinal cord injury -LRB- SCI -RRB- models , including Schwann cells -LRB- Paino et al. , 1994 ; Xu et al. , 1995 , 1997 -RRB- , embryonic stem cells -LRB- McDonald and Howard , 2002 ; Zhang , 2003 -RRB- , olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004 -RRB- and genetically engineered fibroblasts -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	1923
the rodent spinal cord injury -LRB- SCI -RRB- models , including Schwann cells -LRB- Paino et al. , 1994 ; Xu et al. , 1995 , 1997 -RRB- , embryonic stem cells -LRB- McDonald and Howard , 2002 ; Zhang , 2003 -RRB- , olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004 -RRB- and genetically engineered fibroblasts	1923
the rodent spinal cord injury -LRB- SCI -RRB- models	1923
SCI	1954
Schwann cells -LRB- Paino et al. , 1994 ; Xu et al. , 1995 , 1997 -RRB- , embryonic stem cells -LRB- McDonald and Howard , 2002 ; Zhang , 2003 -RRB- , olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004 -RRB- and genetically engineered fibroblasts	1977
Schwann cells -LRB- Paino et al. , 1994 ; Xu et al. , 1995 , 1997 -RRB- , embryonic stem cells -LRB- McDonald and Howard , 2002 ; Zhang , 2003 -RRB- , olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004 -RRB-	1977
Schwann cells -LRB- Paino et al. , 1994 ; Xu et al. , 1995 , 1997 -RRB-	1977
Schwann cells	1977
Paino et al. , 1994 ; Xu et al. , 1995 , 1997	1992
Paino et al.	1992
Paino	1992
et al.	1998
1994 ; Xu et al.	2006
1994	2006
Xu et al.	2012
Xu	2012
et al.	2015
1995 , 1997	2023
1995	2023
1997	2029
embryonic stem cells -LRB- McDonald and Howard , 2002 ; Zhang , 2003 -RRB-	2036
embryonic stem cells	2036
McDonald and Howard	2058
McDonald	2058
Howard	2071
2002 ; Zhang , 2003	2079
2002	2079
Zhang , 2003	2085
Zhang	2085
2003	2092
olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004 -RRB-	2099
olfactory ensheathing cells -LRB- OECs -RRB-	2099
olfactory ensheathing cells	2099
OECs	2128
Li et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004	2135
Li	2135
et al. , 1997 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004	2138
et al. , 1997	2138
et al.	2138
1997	2146
Ruitenberg et al. , 2003	2152
Ruitenberg	2152
et al. , 2003	2163
et al.	2163
2003	2171
Sasaki et al. , 2004	2177
Sasaki	2177
et al. , 2004	2184
et al.	2184
2004	2192
genetically engineered fibroblasts	2202
Liu	2238
et al. , 1999 ; Jin et al. , 2002	2242
et al.	2242
1999 ; Jin et al.	2250
1999	2250
Jin et al.	2256
Jin	2256
et al.	2260
2002	2268
these cellular grafts	2284
injured axonal regeneration and animals ' functional recovery	2320
injured axonal regeneration	2320
animals ' functional recovery	2352
animals '	2352
further research	2382
they	2416
patients	2442
SCI -LRB- Kwon and Tetzlaff , 2001 -RRB-	2456
SCI	2456
Kwon and Tetzlaff	2461
2001	2480
date	2493
lack of suitable donor sites or ethical and technical problems	2499
lack	2499
suitable donor sites or ethical and technical problems	2507
suitable donor sites	2507
ethical and technical problems	2531
a major limitation of cellular replacement therapies utilized in clinical treatments -LRB- Mata et al. , 2002 ; Kawaguchi et al. , 2004 -RRB-	2572
a major limitation	2572
cellular replacement therapies utilized in clinical treatments -LRB- Mata et al. , 2002 ; Kawaguchi et al. , 2004 -RRB-	2594
cellular replacement therapies	2594
clinical treatments -LRB- Mata et al. , 2002 ; Kawaguchi et al. , 2004 -RRB-	2637
clinical treatments	2637
Mata	2658
et al. , 2002 ; Kawaguchi et al. , 2004	2663
et al.	2663
2002 ; Kawaguchi et al.	2671
2002	2671
Kawaguchi et al.	2677
Kawaguchi	2677
et al.	2687
2004	2695
we and others	2713
a more readily accessible source of human cells , preferably with the potential for autologous transplantation ,	2747
a more readily accessible source of human cells	2747
a more readily accessible source	2747
human cells	2783
the potential for autologous transplantation	2812
the potential	2812
autologous transplantation	2830
Feron et al. , 1998 ; Roisen et al. , 2001	2869
Feron	2869
et al. , 1998 ; Roisen et al. , 2001	2875
et al. , 1998	2875
et al.	2875
1998	2883
Roisen et al. , 2001	2889
Roisen	2889
et al. , 2001	2896
et al.	2896
2001	2904
The olfactory neuroepithelium -LRB- ONe -RRB-	2911
The olfactory neuroepithelium	2911
ONe	2942
other regions of the CNS	2969
other regions	2969
the CNS	2986
it	2995
the capacity to continually replace damaged neurons and glia throughout life -LRB- Calof and Chikaraishi , 1989 ; Sosnowski et al. , 1995 -RRB-	3002
damaged neurons and glia	3038
life -LRB- Calof and Chikaraishi , 1989 ; Sosnowski et al. , 1995 -RRB-	3074
life	3074
Calof and Chikaraishi	3080
Calof	3080
Chikaraishi	3090
1989 ; Sosnowski et al. , 1995	3103
1989	3103
Sosnowski et al. , 1995	3109
Sosnowski	3109
et al. , 1995	3119
et al.	3119
1995	3127
Adult human ONe	3134
a unique source of adult neural progenitors , which can be obtained from an individual without invasive surgery -LRB- Calof and Chikaraishi , 1989 ; Winstead et al. , 2005 -RRB-	3162
a unique source	3162
adult neural progenitors , which can be obtained from an individual without invasive surgery -LRB- Calof and Chikaraishi , 1989 ; Winstead et al. , 2005 -RRB-	3181
adult neural progenitors	3181
an individual	3234
invasive surgery -LRB- Calof and Chikaraishi , 1989 ; Winstead et al. , 2005 -RRB-	3256
invasive surgery	3256
Calof and Chikaraishi	3274
Calof	3274
Chikaraishi	3284
1989 ; Winstead et al. , 2005	3297
1989	3297
Winstead et al. , 2005	3303
Winstead	3303
et al. , 2005	3312
et al.	3312
2005	3320
the last several years	3330
we	3354
the procedures	3367
isolation and culture of adult human ONe-derived neurosphere-forming cells -LRB- NSFCs -RRB-	3386
isolation and culture	3386
adult human ONe-derived neurosphere-forming cells -LRB- NSFCs -RRB-	3411
adult human ONe-derived neurosphere-forming cells	3411
NSFCs	3462
cadavers -LRB- Roisen et al. , 2001 -RRB- or patients undergoing nasal sinus surgery -LRB- Winstead et al. , 2005 -RRB-	3474
cadavers -LRB- Roisen et al. , 2001 -RRB-	3474
cadavers	3474
Roisen	3484
et al. , 2001	3491
et al.	3491
2001	3499
patients undergoing nasal sinus surgery -LRB- Winstead et al. , 2005 -RRB-	3508
patients	3508
nasal sinus surgery -LRB- Winstead et al. , 2005 -RRB-	3528
nasal sinus surgery	3528
Winstead	3549
et al. , 2005	3558
et al.	3558
2005	3566
Serial in vitro studies	3573
Serial	3573
NSFCs	3620
characteristics of neural progenitors , indicated by a remarkable level of proliferation and viability -LRB- Zhang et al. , 2004 ; Marshall et al. , 2005 ; Othman et al. , 2005 -RRB- and a stable potential to differentiate along neuronal or glial lineage restriction depending on environmental signals in culture -LRB- Zhang et al. , 2005 , 2006a , b -RRB-	3631
characteristics of neural progenitors , indicated by a remarkable level of proliferation and viability -LRB- Zhang et al. , 2004 ; Marshall et al. , 2005 ; Othman et al. , 2005 -RRB-	3631
characteristics of neural progenitors , indicated by a remarkable level of proliferation and viability	3631
characteristics	3631
neural progenitors	3650
a remarkable level of proliferation and viability	3683
a remarkable level	3683
proliferation and viability	3705
Zhang et al. , 2004 ; Marshall et al. , 2005 ; Othman et al. , 2005	3734
Zhang	3734
et al. , 2004 ; Marshall et al. , 2005 ; Othman et al. , 2005	3740
et al. , 2004	3740
et al.	3740
2004	3748
Marshall et al. , 2005	3754
Marshall	3754
et al. , 2005	3763
et al.	3763
2005	3771
Othman et al. , 2005	3777
Othman	3777
et al. , 2005	3784
et al.	3784
2005	3792
a stable potential to differentiate along neuronal or glial lineage restriction depending on environmental signals in culture -LRB- Zhang et al. , 2005 , 2006a , b -RRB-	3802
a stable potential	3802
neuronal or glial lineage restriction	3844
environmental signals in culture	3895
environmental signals	3895
culture	3920
Zhang	3929
et al. , 2005 , 2006a , b	3935
et al.	3935
2005	3943
2006a	3949
b	3955
NSFCs lines	3972
nerve growth factor , brainderived neurotrophic factor -LRB- BDNF -RRB- regardless of passage number , donor age or donor sex -LRB- Xiao et al. , 2005 -RRB-	3992
nerve growth factor	3992
neurotrophic factor -LRB- BDNF -RRB-	4026
neurotrophic factor	4026
BDNF	4047
passage number , donor age or donor sex -LRB- Xiao et al. , 2005 -RRB-	4067
passage number	4067
donor age or donor sex -LRB- Xiao et al. , 2005 -RRB-	4083
donor age or donor sex	4083
Xiao	4107
et al. , 2005	4112
et al.	4112
2005	4120
One-week delayed transplantation of GFP-labeled NSFCs into a partial cervical hemisection	4127
One-week delayed transplantation	4127
GFP-labeled NSFCs into a partial cervical hemisection	4163
GFP-labeled NSFCs	4163
a partial cervical hemisection	4186
PCHX	4218
rat model	4224
NSFCs	4266
host spinal cord and rescue axotomized rubrospinal tract -LRB- RST -RRB- neurons from retrograde atrophy	4308
host spinal cord	4308
rescue axotomized rubrospinal tract -LRB- RST -RRB- neurons from retrograde atrophy	4329
rescue	4329
rubrospinal tract -LRB- RST -RRB- neurons from retrograde atrophy	4347
rubrospinal tract -LRB- RST -RRB- neurons	4347
RST	4366
retrograde atrophy	4384
RST axonal regeneration that leads to functional recovery -LRB- Xiao et al. , 2005 -RRB-	4422
RST axonal regeneration	4422
functional recovery -LRB- Xiao et al. , 2005 -RRB-	4460
functional recovery	4460
Xiao	4481
et al. , 2005	4486
et al.	4486
2005	4494
the potential for using the ONe progenitors for future autologous cell replacement strategies in the SCI	4530
the potential	4530
the ONe progenitors	4554
future autologous cell replacement strategies	4578
the SCI	4627
the present study	4636
the effects of NSFCs	4687
the effects	4687
NSFCs	4702
reinnervation of axotomized RST axons following the acute PCHX	4711
reinnervation	4711
axotomized RST axons following the acute PCHX	4728
axotomized RST axons	4728
the acute PCHX	4759
forelimb functional recovery	4801
irreversible and reversible lesions of regenerated RST	4833
irreversible and reversible lesions	4833
regenerated RST	4872
Materials and methods	4890
Materials	4890
methods	4904
Preparation of GFP-labeled NSFCs for engraftment The culture of GFP-labeled NSFCs for engraftment has been described previously	4912
Preparation	4912
GFP-labeled NSFCs for engraftment	4927
GFP-labeled NSFCs	4927
engraftment	4949
The culture of GFP-labeled NSFCs for engraftment	4961
The culture	4961
GFP-labeled NSFCs for engraftment	4976
GFP-labeled NSFCs	4976
engraftment	4998
Xiao et al. , 2005	5041
Xiao	5041
et al.	5046
2005	5054
brief	5064
two patient specific ONe-derived NSFCs lines	5071
two patient	5071
specific ONe-derived NSFCs lines	5083
green fluorescent protein -LRB- GFP -RRB-	5160
green fluorescent protein	5160
GFP	5187
the LERS -- EGFP vector -LRB- Kinsella and Nolan , 1996 -RRB-	5198
the LERS	5198
EGFP vector -LRB- Kinsella and Nolan , 1996 -RRB-	5208
EGFP vector	5208
Kinsella and Nolan , 1996	5221
Kinsella	5221
Nolan , 1996	5234
Nolan	5234
1996	5241
transfection	5254
the GFP	5268
> 60 % of the cells	5300
>	5300
the cells	5308
These cells	5319
up to 40 passages	5349
representative passages	5371
liquid nitrogen for transplantation	5410
liquid nitrogen	5410
transplantation	5430
1 week prior to engraftment	5450
1 week	5450
engraftment	5466
GFP-labeled NSFCs	5479
frozen stock	5516
Minimal Essential Medium -LRB- MEM -RRB- +10 %	5561
Minimal Essential Medium	5561
MEM	5587
+10 %	5592
fetal bovine serum -LRB- FBS -RRB- ; after which they were weaned from FBS 10 % , 5 % to 2.5 % every 2 days in vitro	5597
fetal bovine serum	5597
FBS	5617
they	5635
FBS 10 % , 5 % to 2.5 % every 2 days	5657
FBS 10 %	5657
FBS	5657
5 % to 2.5 % every	5666
2 days	5683
MEM	5719
+2.5 % FBS	5722
+2.5 %	5722
FBS	5728
15 to 30 min prior to injection	5736
15 to 30 min	5736
injection	5758
NSFCs	5769
the culture surface	5794
lowspeed centrifugation	5827
MEM +2.5 % FBS and Matrigel ® matrix -LRB- 1:1 , BD Biosciences -RRB- at a concentration of 2 ×	5877
MEM +2.5 % FBS	5877
MEM	5877
+2.5 % FBS	5880
Matrigel ® matrix -LRB- 1:1 , BD Biosciences -RRB- at a concentration of 2 ×	5894
Matrigel ® matrix -LRB- 1:1 , BD Biosciences -RRB-	5894
Matrigel ® matrix	5894
1:1	5912
BD Biosciences	5917
a concentration of 2 ×	5936
a concentration	5936
2 ×	5955
104 cells/μl	5957
4 °C	5988
The remaining cells	5994
3 -- 4 days for immunocytochemical characterization and RT -- PCR and ELISA of cell lysates for BDNF as previously described -LRB- Xiao et al. , 2005 -RRB-	6045
3	6045
4 days for immunocytochemical characterization and RT -- PCR and ELISA of cell lysates for BDNF as previously described -LRB- Xiao et al. , 2005 -RRB-	6047
4 days for immunocytochemical characterization and RT	6047
4 days	6047
immunocytochemical characterization and RT	6058
PCR and ELISA of cell lysates for BDNF as previously described -LRB- Xiao et al. , 2005 -RRB-	6101
PCR and ELISA	6101
cell lysates for BDNF as previously described -LRB- Xiao et al. , 2005 -RRB-	6118
cell lysates	6118
BDNF as previously described -LRB- Xiao et al. , 2005 -RRB-	6135
BDNF	6135
Xiao	6165
et al. , 2005	6170
et al.	6170
2005	6178
Experimental paradigm Fifty-two female adult Sprague Dawley rats	6185
Experimental paradigm	6185
Fifty-two female adult Sprague Dawley rats	6207
experimental group -LRB- n = 48 -RRB- and normal control group -LRB- n = 4 -RRB-	6268
experimental group	6268
n	6288
48	6290
normal control group	6298
n	6320
4	6322
an introductory period of 2 weeks	6332
an introductory period	6332
2 weeks	6358
the rats	6367
their forelimb posture	6394
the data	6421
the baseline data	6449
surgery	6476
Normal control rats	6485
dextran amine -LRB- BDA -RRB- injection to establish baseline data for anterograde tracing from the RN	6527
dextran amine	6527
BDA	6542
injection	6547
baseline data	6570
anterograde tracing from the RN	6588
anterograde	6588
the RN	6613
All rats in the experimental group	6621
All rats	6621
the experimental group	6633
a PCHX of the right mid-cervical -LRB- C3 -- 4 -RRB- cord and either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB- or Matrigel ® matrix alone -LRB- n = 18 -RRB-	6665
a PCHX	6665
the right mid-cervical -LRB- C3 -- 4 -RRB- cord and either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB- or Matrigel ® matrix alone -LRB- n = 18 -RRB-	6675
the right mid-cervical	6675
C3 -- 4 -RRB- cord and either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB- or Matrigel ® matrix alone -LRB- n = 18	6699
C3 -- 4 -RRB- cord and either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB-	6699
C3	6699
4 -RRB- cord and either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB-	6702
cord	6705
either a transplant of GFP-labeled NSFCs suspended in Matrigel ® matrix -LRB- n = 30 -RRB-	6714
either a transplant	6714
GFP-labeled NSFCs suspended in Matrigel ® matrix	6737
GFP-labeled NSFCs	6737
Matrigel ® matrix	6768
n	6786
30	6788
Matrigel ® matrix alone -LRB- n = 18	6795
Matrigel	6795
® matrix alone -LRB- n = 18	6803
® matrix alone	6803
n = 18	6819
n	6819
18	6821
These rats	6826
12 weeks for forelimb posture and spontaneous vertical exploration	6862
12 weeks	6862
forelimb posture and spontaneous vertical exploration	6875
forelimb posture	6875
spontaneous vertical exploration	6896
12 weeks	6933
the animals	6960
three subgroups	6999
Animals in the first subgroup -LRB- n = 24 -RRB-	7016
Animals	7016
the first subgroup -LRB- n = 24 -RRB-	7027
the first subgroup	7027
n	7047
24	7049
a BDA injection	7062
the left RN	7083
an additional 2 weeks	7108
immunohistochemistry and immunoelectron microscopic analysis	7156
Animals in the second subgroup -LRB- n = 12 -RRB-	7218
Animals	7218
the second subgroup -LRB- n = 12 -RRB-	7229
the second subgroup	7229
n	7250
12	7252
a dorsolateral funiculotomy -LRB- DLF -RRB-	7265
a dorsolateral funiculotomy	7265
DLF	7294
C2	7302
the right RST followed by behavioral testing weekly for 4 additional weeks before sacrifice	7314
the right RST	7314
behavioral testing weekly for 4 additional weeks	7340
behavioral testing weekly	7340
4 additional weeks	7370
sacrifice	7396
Animals in the third subgroup -LRB- n = 12 -RRB-	7407
Animals	7407
the third subgroup -LRB- n = 12 -RRB-	7418
the third subgroup	7418
n	7438
12	7440
an injection of muscimol or saline	7453
an injection	7453
muscimol or saline	7469
the left RN	7493
RN neuronal function	7525
posture and use	7556
10 -- 12 h after injection , and 48 h after injection after recovery	7594
10 -- 12 h after injection	7594
10	7594
12 h after injection	7597
12 h	7597
injection	7608
48 h after injection after recovery	7623
48 h	7623
injection after recovery	7634
injection	7634
recovery	7650
2 days later	7660
these animals	7674
an additional injection of muscimol or saline	7697
an additional injection	7697
muscimol or saline	7724
histological study	7772
All animals in the experimental groups	7792
All animals	7792
the experimental groups	7807
an identical protocol	7840
prevention of inflammation	7866
prevention	7866
inflammation	7880
penicillin and immunosuppression	7898
cyclosporine as previously described -LRB- Xiao et al. , 2005 -RRB-	7936
cyclosporine	7936
Xiao	7974
et al. , 2005	7979
et al.	7979
2005	7987
All the above procedures	7994
the Animal Care and Use Committee of Nanjing Medical University	8036
the Animal Care and Use Committee	8036
Nanjing Medical University	8073
accord with the National Institutes of Health guidelines for the care and use of laboratory animals	8112
accord	8112
the National Institutes of Health guidelines for the care and use of laboratory animals	8124
the National Institutes of Health guidelines	8124
Health	8151
the care and use of laboratory animals	8173
the care and use	8173
laboratory animals	8193
Surgical procedures	8213
The unilateral C3 -- 4 PCHX was performed as previously described	8233
The unilateral C3	8233
4 PCHX	8251
Liu et al. , 1999 , Xiao et al. , 2005	8297
Liu	8297
et al. , 1999 , Xiao et al. , 2005	8301
et al.	8301
1999	8309
Xiao et al.	8315
Xiao	8315
et al.	8320
2005	8328
rats	8344
an intraperitoneal injection of ketamine , 100 mg/kg , and xylazine , 10 mg/kg	8377
an intraperitoneal injection	8377
ketamine , 100 mg/kg , and xylazine , 10 mg/kg	8409
ketamine	8409
100 mg/kg	8419
xylazine , 10 mg/kg	8434
xylazine	8434
10 mg/kg	8444
The spinal cord	8454
dorsal laminectomy of the C3 and C4 vertebrae	8485
dorsal laminectomy	8485
the C3 and C4 vertebrae	8507
a cavity	8536
1.5 mm	8545
microscissors and gentle aspiration	8573
microscissors	8573
gentle aspiration	8591
the right lateral funiculus of the spinal cord	8612
the right lateral funiculus	8612
the spinal cord	8643
The lesion	8660
the axons of the RST in the right dorsolateral and lateral funiculi , partly	8690
the axons	8690
the RST in the right dorsolateral and lateral funiculi , partly	8703
the RST in the right dorsolateral	8703
the RST	8703
the right dorsolateral	8714
lateral funiculi , partly	8741
lateral funiculi	8741
the right dorsal and ventral columns and gray matter	8774
the right dorsal	8774
ventral columns and gray matter	8795
ventral columns	8795
gray matter	8815
the left dorsal column	8832
A piece of gel foam	8872
A piece	8872
gel foam	8883
the cavity	8906
the bleeding	8925
5 min	8956
GFP-labeled NSFCs , 8 -- 10 μl -LRB- 2 × 104 cells/μl -RRB- ,	8963
GFP-labeled NSFCs	8963
8 -- 10 μl -LRB- 2 × 104 cells/μl -RRB-	8982
8	8982
10 μl -LRB- 2 × 104 cells/μl -RRB-	8984
2 × 104 cells/μl	8991
2 ×	8991
104 cells/μl	8993
MEM	9021
+2.5 % FBS and Matrigel ® matrix -LRB- 1:1 -RRB- or MEM +2.5 % FBS and Matrigel ® matrix alone was drawn into a 25 μl Hamilton syringe attached to a glass pipette -LRB- 50 μm tip diameter -RRB-	9024
+2.5 % FBS and Matrigel ® matrix -LRB- 1:1 -RRB-	9024
+2.5 %	9024
FBS and Matrigel ® matrix -LRB- 1:1 -RRB-	9030
FBS and Matrigel ® matrix	9030
1:1	9056
MEM +2.5 % FBS and Matrigel ® matrix alone was drawn into a 25 μl Hamilton syringe attached to a glass pipette -LRB- 50 μm tip diameter -RRB-	9064
MEM +2.5 % FBS and Matrigel ® matrix alone was drawn into a 25 μl Hamilton syringe attached to a glass pipette	9064
MEM +2.5 % FBS and Matrigel ® matrix alone was drawn into a 25 μl	9064
MEM	9064
+2.5 % FBS and Matrigel ® matrix	9067
+2.5 % FBS	9067
Matrigel ® matrix	9081
a 25 μl	9119
Hamilton syringe attached to a glass pipette	9127
Hamilton syringe	9127
a glass pipette	9156
50 μm tip diameter	9173
The syringe	9194
1	9231
2 min	9233
the Matrigel ® matrix	9248
the gel	9298
the lesion site	9331
The dura mater and muscles	9348
The dura mater	9348
muscles	9367
sutures	9392
the skin	9406
wound clips	9431
DLF	9448
animals	9453
a second laminectomy	9496
the level of C2	9520
the level	9520
C2	9533
removal of the right dorsolateral quadrant using the same procedure as described above	9549
removal	9549
the right dorsolateral quadrant using the same procedure as described above	9560
the right dorsolateral quadrant	9560
the same procedure	9598
muscimol or BDA injection	9641
animals	9668
a stereotaxic apparatus	9731
the coordinates described previously -LRB- Mori et al. , 1997 -RRB-	9769
the	9769
Mori et al. , 1997	9807
Mori	9807
et al.	9812
1997	9820
the magnocellular portion of the left RN	9827
the magnocellular portion	9827
the left RN	9856
the injection site	9886
Three-tenths of a microliter of 0.1 % muscimol -LRB- Sigma , Chemical , CO -RRB- or 10 % BDA -LRB- Molecular Probes , Leiden , The Netherlands -RRB- in 0.9 % saline solution -LRB- or saline alone -RRB-	9906
Three-tenths	9906
a microliter of 0.1 % muscimol -LRB- Sigma , Chemical , CO -RRB- or 10 % BDA -LRB- Molecular Probes , Leiden , The Netherlands -RRB- in 0.9 % saline solution -LRB- or saline alone -RRB-	9922
a microliter of 0.1 % muscimol -LRB- Sigma , Chemical , CO -RRB-	9922
a microliter	9922
0.1 % muscimol -LRB- Sigma , Chemical , CO -RRB-	9938
0.1 % muscimol	9938
Sigma	9953
Chemical	9960
CO	9970
10 % BDA -LRB- Molecular Probes , Leiden , The Netherlands -RRB- in 0.9 % saline solution -LRB- or saline alone -RRB-	9977
10 % BDA -LRB- Molecular Probes , Leiden , The Netherlands -RRB-	9977
10 % BDA	9977
Molecular Probes	9986
Leiden	10004
The Netherlands	10012
0.9 % saline solution -LRB- or saline alone -RRB-	10032
0.9 % saline solution	10032
saline alone	10057
saline	10057
5 -- 6 min in six 50-nl pulses	10097
5	10097
6 min in six 50-nl pulses	10099
6 min	10099
six 50-nl pulses	10108
a micropipette -LRB- tip diameter 30 -- 40 μm -RRB- attached to a 1-μl Hamilton syringe	10133
a micropipette	10133
tip diameter	10149
30 -- 40 μm	10162
30	10162
40 μm	10165
a 1-μl Hamilton syringe	10184
The needle	10209
place for an additional 20 min	10232
place	10232
an additional 20 min	10242
2 -- 3 min	10293
2	10293
3 min	10295
posture and behavioral testing Forelimb posture	10311
posture	10311
behavioral testing Forelimb posture	10323
different times	10375
the operation to study reinnervation of the forelimb	10397
reinnervation of the forelimb	10420
reinnervation	10420
the forelimb	10437
Flexion of the forepaw	10451
Flexion	10451
the forepaw	10462
the animals	10492
anesthesia	10519
An initial deficit in this respect	10555
An initial deficit	10555
this respect	10577
damage	10609
the RST following the PCHX	10619
the RST	10619
the PCHX	10637
Forelimb use during vertical exploration	10647
Forelimb use	10647
vertical exploration	10667
a highly sensitive test for asymmetries of limb function	10691
a highly sensitive test	10691
asymmetries of limb function	10719
asymmetries	10719
limb function	10734
repeated testing	10753
the asymmetry score -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	10789
the asymmetry score	10789
Liu	10810
et al. , 1999 ; Jin et al. , 2002	10814
et al.	10814
1999 ; Jin et al.	10822
1999	10822
Jin et al.	10828
Jin	10828
et al.	10832
2002	10840
The rats	10847
one	10867
preoperative test	10871
engraftment	10920
All behavioral performance tests	10933
a double-blind study	10984
The procedure for this behavioral test	11006
The procedure	11006
this behavioral test	11024
Xiao et al. , 2005	11071
Xiao	11071
et al.	11076
2005	11084
brief	11094
rats	11101
a clear glass cylinder 20 cm in diameter and 30 cm high for 5 min	11121
a clear glass cylinder 20 cm in diameter	11121
a clear glass cylinder 20 cm	11121
diameter	11153
30 cm high for 5 min	11166
30 cm	11166
5 min	11181
independent use of the left forelimb , right forelimb , or both	11202
independent use	11202
the left forelimb , right forelimb , or both	11221
the left forelimb	11221
right forelimb	11240
both	11259
the wall of the cylinder	11279
the wall	11279
the cylinder	11291
vertical posturing	11311
Each behavior	11331
terms of percent forelimb use of the left , right or both relative	11362
terms	11362
percent forelimb use of the left , right or both relative	11371
percent forelimb use	11371
the left , right or both relative	11395
the left	11395
right	11405
both relative	11414
the total	11431
Tissue preparation Animals	11442
an overdose of ketamine and xylazine , perfused through the heart with 200 ml of 0.01 M PBS , pH 7.4	11499
an overdose	11499
ketamine and xylazine	11514
the heart with 200 ml of 0.01 M PBS , pH 7.4	11554
the heart	11554
200 ml of 0.01 M PBS , pH 7.4	11569
200 ml	11569
0.01 M PBS , pH 7.4	11579
0.01 M PBS	11579
pH 7.4	11591
500 ml of an ice-cold , freshly prepared solution of 4 % formaldehyde	11611
500 ml	11611
an ice-cold , freshly prepared solution of 4 % formaldehyde	11621
an ice-cold , freshly prepared solution	11621
4 % formaldehyde	11663
immunofluorescent histochemistry	11692
0.5 % glutaraldehyde -LRB- for immunoelectron microscopy -RRB- in 0.1 M PB -LRB- pH 7.4 -RRB-	11734
0.5 % glutaraldehyde	11734
immunoelectron microscopy	11759
0.1 M PB -LRB- pH 7.4 -RRB-	11789
0.1 M PB	11789
pH 7.4	11799
The midbrain and the whole spinal cord , including the dorsal roots	11808
The midbrain	11808
the whole spinal cord	11825
the dorsal roots	11858
the same fixative at 4 °C overnight followed by cytoprotection in PB containing 30 % sucrose for 1 -- 2 days at 4 °C	11910
the same fixative at 4 °C overnight followed by cytoprotection in PB containing 30 % sucrose for 1	11910
the same fixative at 4 °C overnight	11910
the same fixative at 4 °C	11910
the same fixative	11910
4 °C	11931
cytoprotection in PB	11958
cytoprotection	11958
PB	11976
30 % sucrose	11990
1	12006
2 days at 4 °C	12008
2 days	12008
4 °C	12018
Spinal cord and midbrain	12024
Spinal cord	12024
midbrain	12040
OCT compound	12066
20 μm	12099
a cryostat	12108
gelatin-coated slides	12134
immunoelectron microscopic processing	12161
the specimens	12200
the coronal plane with a vibratome -LRB- Leica , Germany -RRB-	12226
the coronal plane	12226
a vibratome -LRB- Leica , Germany -RRB-	12249
a vibratome	12249
Leica	12262
Germany	12269
sections with a thickness of 50 μm	12283
sections	12283
a thickness of 50 μm	12297
a thickness	12297
50 μm	12312
0.1 M PB -LRB- pH 7.4 -RRB-	12335
0.1 M PB	12335
pH 7.4	12345
Histology and immunocytochemistry Toluidine blue and immunocytochemical staining procedures	12354
Histology	12354
immunocytochemistry Toluidine blue and immunocytochemical staining procedures	12368
immunocytochemistry Toluidine	12368
blue and immunocytochemical staining procedures	12398
Xiao et al. , 2005	12476
Xiao	12476
et al.	12481
2005	12489
immunocytochemistry	12500
sections	12530
4 °C	12571
a rabbit polyclonal anti-GFP antibody -LRB- 1:100 ; Chemicon , Temecula , CA , USA -RRB- and mouse monoclonal anti-glial fibrillary acidic protein -LRB- GFAP -RRB- antibody -LRB- 1:300 ; Chemicon , Temecula , CA , USA -RRB- , mouse monoclonal anti-microtubule associated protein -LRB- MAP-2 -RRB- antibody -LRB- 1:200 ; Sigma , St. Louis , MO , USA -RRB- , mouse monoclonal anti-BDNF antibody -LRB- 1:200 ; Chemicon , Temecula , CA , USA -RRB- , or mouse monoclonal anti-ED-1 antibody -LRB- 1:400 ; Chemicon , Temecula , CA , USA -RRB- , respectively	12581
a rabbit	12581
polyclonal anti-GFP antibody -LRB- 1:100 ; Chemicon , Temecula , CA , USA -RRB- and mouse monoclonal anti-glial fibrillary acidic protein -LRB- GFAP -RRB-	12590
polyclonal anti-GFP antibody	12590
1:100 ; Chemicon , Temecula , CA , USA	12620
1:100	12620
Chemicon , Temecula , CA , USA	12627
mouse monoclonal anti-glial fibrillary acidic protein	12660
GFAP	12715
antibody -LRB- 1:300 ; Chemicon , Temecula , CA , USA -RRB- , mouse monoclonal anti-microtubule associated protein -LRB- MAP-2 -RRB- antibody -LRB- 1:200 ; Sigma , St. Louis , MO , USA -RRB- , mouse monoclonal anti-BDNF antibody -LRB- 1:200 ; Chemicon , Temecula , CA , USA -RRB- , or mouse monoclonal anti-ED-1 antibody -LRB- 1:400 ; Chemicon , Temecula , CA , USA -RRB- , respectively	12721
antibody -LRB- 1:300 ; Chemicon , Temecula , CA , USA -RRB-	12721
antibody	12721
1:300 ; Chemicon , Temecula , CA , USA	12731
1:300	12731
Chemicon , Temecula , CA , USA	12738
mouse monoclonal anti-microtubule associated protein -LRB- MAP-2 -RRB- antibody -LRB- 1:200 ; Sigma , St. Louis , MO , USA -RRB- , mouse monoclonal anti-BDNF antibody -LRB- 1:200 ; Chemicon , Temecula , CA , USA -RRB- , or mouse monoclonal anti-ED-1 antibody -LRB- 1:400 ; Chemicon , Temecula , CA , USA -RRB- , respectively	12768
mouse monoclonal anti-microtubule associated protein -LRB- MAP-2 -RRB- antibody -LRB- 1:200 ; Sigma , St. Louis , MO , USA -RRB-	12768
mouse monoclonal anti-microtubule	12768
mouse	12768
protein -LRB- MAP-2 -RRB- antibody -LRB- 1:200 ; Sigma , St. Louis , MO , USA -RRB-	12813
protein -LRB- MAP-2 -RRB- antibody	12813
protein -LRB- MAP-2 -RRB-	12813
protein	12813
MAP-2	12822
1:200	12839
Sigma , St. Louis , MO , USA	12846
Sigma	12846
St. Louis	12853
MO	12864
USA	12868
mouse monoclonal anti-BDNF antibody -LRB- 1:200 ; Chemicon , Temecula , CA , USA -RRB-	12874
mouse monoclonal anti-BDNF antibody	12874
1:200 ; Chemicon , Temecula , CA , USA	12911
1:200	12911
Chemicon , Temecula , CA , USA	12918
mouse monoclonal anti-ED-1 antibody -LRB- 1:400 ; Chemicon , Temecula , CA , USA -RRB- , respectively	12951
mouse monoclonal anti-ED-1 antibody -LRB- 1:400 ; Chemicon , Temecula , CA , USA -RRB-	12951
mouse monoclonal anti-ED-1 antibody	12951
1:400 ; Chemicon , Temecula , CA , USA	12988
1:400	12988
Chemicon , Temecula , CA , USA	12995
secondary antibodies , Texas Red-conjugate goat anti-mouse IgG and FITC-conjugate goat anti-rabbit IgG diluted 1:100 -LRB- Texas Red , Molecular Probes , Eugene , OR , USA ; FITC , Cappel , West Chester , PA , USA -RRB-	13054
secondary antibodies	13054
Texas Red-conjugate goat anti-mouse IgG and FITC-conjugate goat anti-rabbit IgG diluted 1:100 -LRB- Texas Red , Molecular Probes , Eugene , OR , USA ; FITC , Cappel , West Chester , PA , USA -RRB-	13076
Texas Red-conjugate goat anti-mouse IgG and FITC-conjugate goat anti-rabbit IgG	13076
Texas Red-conjugate goat	13076
anti-mouse IgG and FITC-conjugate goat	13101
anti-rabbit IgG	13140
1:100 -LRB- Texas Red , Molecular Probes , Eugene , OR , USA ; FITC , Cappel , West Chester , PA , USA -RRB-	13164
1:100	13164
Texas Red , Molecular Probes , Eugene , OR	13171
Texas Red	13171
Molecular Probes	13182
Eugene	13200
OR	13208
USA ; FITC , Cappel , West Chester , PA , USA	13212
USA	13212
FITC , Cappel , West Chester , PA , USA	13217
FITC	13217
Cappel	13223
West Chester	13231
PA	13245
USA	13249
GFAP and ED-1 staining	13272
sections	13296
a biotinylated goat anti rabbit IgG -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- and avidin -- biotin -- peroxidase complex -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- for 1 h at room temperature	13336
a	13336
goat anti rabbit IgG -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- and avidin -- biotin -- peroxidase complex -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- for 1 h	13351
goat anti rabbit IgG -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB-	13351
goat	13351
anti rabbit IgG -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB-	13356
anti rabbit IgG	13356
1:150 , Vector laboratories , Burlingame , CA , USA	13373
1:150	13373
Vector laboratories	13380
Burlingame	13401
CA	13413
USA	13417
avidin -- biotin -- peroxidase complex -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- for 1 h	13426
avidin -- biotin	13426
avidin	13426
biotin	13434
peroxidase complex -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB- for 1 h	13441
peroxidase complex -LRB- 1:150 , Vector laboratories , Burlingame , CA , USA -RRB-	13441
peroxidase complex	13441
1:150 , Vector laboratories , Burlingame , CA , USA	13461
1:150	13461
Vector laboratories	13468
Burlingame	13489
CA	13501
USA	13505
1 h	13514
room temperature	13521
The immunoreactive product	13539
hydrogen peroxidase and diaminobenzidine	13587
chromogen	13631
Omission of primary or secondary antibodies	13642
Omission	13642
primary or secondary antibodies	13654
the specificity of the reaction	13694
the specificity	13694
the reaction	13713
BDA immunofluorescence	13731
sections of spinal cord or midbrain from the sixteen BDA tracing rats	13755
sections of spinal cord	13755
sections	13755
spinal cord	13767
midbrain from the sixteen BDA tracing rats	13782
the sixteen BDA tracing	13796
the sixteen BDA	13796
biotin	13843
FITC -LRB- Sigma , St. Louis , MO , USA -RRB-	13850
FITC	13850
Sigma	13856
St. Louis	13863
MO , USA	13874
previous procedures -LRB- Liu et al. , 1999 ; Xiao et al. , 2005 -RRB-	13889
previous procedures	13889
Liu	13910
et al. , 1999 ; Xiao et al. , 2005	13914
et al.	13914
1999 ; Xiao et al.	13922
1999	13922
Xiao et al.	13928
Xiao	13928
et al.	13933
2005	13941
biotin -- FITC/synapsin I	13952
biotin	13952
FITC/synapsin I	13960
FITC/synapsin	13960
I	13974
spinal cord sections	13977
4 °C	14026
goat anti-biotin FITC conjugate antibody -LRB- 1:50 -RRB- , rinsed three times for 30 min with PBS	14036
goat	14036
anti-biotin FITC conjugate antibody -LRB- 1:50 -RRB- ,	14041
anti-biotin FITC conjugate antibody	14041
1:50	14078
three times	14092
30 min	14108
PBS	14120
4 °C	14148
rabbit polyclonal anti-synapsin I antibody -LRB- 1:100 ; Sigma , St. Louis , MO , USA -RRB- rinsed three times for 10 min each with PBS	14158
rabbit	14158
I antibody -LRB- 1:100 ; Sigma , St. Louis , MO , USA -RRB-	14190
I antibody	14190
1:100	14202
Sigma , St. Louis , MO , USA	14209
Sigma	14209
St. Louis	14216
MO	14227
USA	14231
three times	14243
10 min each	14259
10 min	14259
each	14266
PBS	14276
room temperature	14297
the secondary antibodies Texas Red-conjugate donkey anti-rabbit IgG -LRB- 1:150 ; Molecular Probes , Eugene , OR , USA -RRB- for 1 h. Sections were rinsed and mounted	14319
the secondary antibodies Texas Red-conjugate	14319
donkey anti-rabbit IgG -LRB- 1:150 ; Molecular Probes , Eugene , OR , USA -RRB- for 1 h. Sections	14364
donkey anti-rabbit IgG -LRB- 1:150 ; Molecular Probes , Eugene , OR , USA -RRB-	14364
donkey anti-rabbit IgG	14364
1:150	14388
Molecular Probes , Eugene , OR , USA	14395
Molecular Probes	14395
Eugene	14413
OR	14421
USA	14425
1 h. Sections	14434
Primary or secondary antibody omission	14473
Primary	14473
secondary antibody omission	14484
the specificity of each reaction	14534
the specificity	14534
each reaction	14553
BDA immunoelectron microscopic processing	14572
sections of C6 -- 7 segments	14615
sections	14615
C6 -- 7 segments	14627
C6	14627
7 segments	14630
other eight BDA tracing rats were stained with an ABC elite kit -LRB- Vector -RRB- and visualized with nickelintensified diaminobenzidine -LRB- Kuchler et al. , 2002 -RRB-	14646
other eight BDA	14646
eight	14652
rats	14670
an ABC elite kit -LRB- Vector -RRB-	14693
an ABC elite kit	14693
Vector	14711
nickelintensified diaminobenzidine	14739
Kuchler	14775
et al. , 2002	14783
et al.	14783
2002	14791
freefloating sections	14807
three times , 30 min each ,	14841
three times	14841
30 min each	14854
30 min	14854
each	14861
TBST -LRB- 50 mM Tris-buffered saline , pH 7.4 -RRB- , then incubated overnight with an avidin -- biotin -- peroxidase complex at room temperature -LRB- ABC ; Vectastain Elite ABC Kit , Vector Laboratories , USA -RRB-	14870
TBST -LRB- 50 mM Tris-buffered saline , pH 7.4 -RRB-	14870
TBST	14870
50 mM Tris-buffered saline , pH 7.4	14876
50 mM	14876
Tris-buffered saline	14882
pH 7.4	14904
overnight	14928
an avidin -- biotin -- peroxidase complex	14943
an avidin	14943
biotin	14953
peroxidase complex	14960
room temperature -LRB- ABC ; Vectastain Elite ABC Kit , Vector Laboratories , USA -RRB-	14982
room temperature	14982
ABC	15000
Vectastain Elite ABC Kit , Vector Laboratories , USA	15005
Vectastain Elite ABC Kit	15005
Vector Laboratories	15031
USA	15052
the second day	15061
three 30-min rinses in TBST	15083
three 30-min rinses	15083
TBST	15106
the sections	15112
nickel-intensified diaminobenzidine -LRB- Sigma , St. Louis , MO , USA -RRB- for 10 -- 15 min	15146
nickel-intensified diaminobenzidine -LRB- Sigma , St. Louis , MO , USA -RRB- for 10	15146
nickel-intensified diaminobenzidine -LRB- Sigma , St. Louis , MO , USA -RRB-	15146
nickel-intensified diaminobenzidine	15146
Sigma	15183
St. Louis	15190
MO , USA	15201
10	15214
15 min	15217
buffer washes	15235
sections	15250
slides for light microscopic examination	15289
slides	15289
light microscopic examination	15300
electron microscopy	15347
sections	15396
2 %	15424
osmium tetroxide solution for 1 h , dehydrated in an ascending alcohol series , and embedded in durcupan resin	15427
osmium tetroxide solution for 1 h	15427
osmium tetroxide solution	15427
1 h	15457
an ascending alcohol series	15476
durcupan resin	15521
areas of the ventral horn	15546
areas	15546
the ventral horn	15555
ultrathin sections -LRB- 70 nm thick -RRB-	15596
ultrathin sections	15596
70 nm	15616
every fifth section	15642
nickel slot grids	15693
uranyl acetate for 30 min	15728
uranyl acetate	15728
30 min	15747
the sections	15758
a CM12 Philips electron microscope	15791
Axonal counts and statistical analysis	15827
Axonal counts	15827
statistical analysis	15845
analysis of BDA-labeled RST axons	15870
analysis	15870
BDA-labeled RST axons	15882
sections of BDAlabeled RST axons	15905
sections	15905
BDAlabeled RST axons	15917
coronal sections of caudal segments of the spinal cord -LRB- C6 -- 8 , T1 -- 4 , T8 , T12 and L1 , three sections for each segment -RRB-	15961
coronal sections	15961
caudal segments of the spinal cord -LRB- C6 -- 8 , T1 -- 4 , T8 , T12 and L1 , three sections for each segment -RRB-	15981
caudal segments	15981
the spinal cord -LRB- C6 -- 8 , T1 -- 4 , T8 , T12 and L1 , three sections for each segment -RRB-	16000
the spinal cord	16000
C6 -- 8 , T1 -- 4 , T8 , T12 and L1 , three sections for each segment	16017
C6 -- 8 , T1 -- 4	16017
C6	16017
8 , T1	16020
8	16020
T1	16023
4	16026
T8 , T12 and L1	16029
T8	16029
T12	16033
L1	16041
three sections for each segment	16045
three sections	16045
each segment	16064
a confocal microscopy	16084
axons in the dorsolateral or lateral funiculi	16120
axons	16120
the dorsolateral or lateral funiculi	16129
None of the labeled collaterals in the gray matter	16180
None	16180
the labeled collaterals in the gray matter	16188
the labeled collaterals	16188
the gray matter	16215
Data obtained from the histological assessments and behavioral tests	16246
Data	16246
the histological assessments and behavioral tests	16265
the histological assessments	16265
behavioral tests	16298
significant differences between animal groups using either Student 's t-test or one-way ANOVA	16333
significant differences	16333
animal groups using either Student 's t-test or one-way ANOVA	16365
animal groups	16365
Student 's t-test or one-way ANOVA	16392
Student 's t-test	16392
Student 's	16392
one-way ANOVA	16412
All quantitative data	16427
mean ± standard deviation -LRB- SD -RRB-	16467
mean ± standard deviation	16467
SD	16492
All graphs	16497
Microsoft Excel software	16528
Results	16555
1	16568
Photomicrographs of the cervical spinal cord showing transplanted NSFCs within the lesion site and their migration into the host cord 12 weeks after transplantation .	16571
Photomicrographs of the cervical spinal cord	16571
Photomicrographs	16571
the cervical spinal cord	16591
transplanted NSFCs	16624
the lesion site and their migration	16650
the lesion site	16650
their migration	16670
the host cord 12 weeks	16691
the host cord	16691
12 weeks	16705
transplantation	16720
-LRB- A -- D -RRB- Coronal sections	16737
A -- D	16738
A	16738
D	16740
host	16768
graft site	16773
Numerous GFP-labeled NSFCs	16785
the lesion cavity	16824
the host cord	16863
interruption at the host -- graft interface -LRB- dashed lines in A , C and D -RRB-	16886
interruption at the host	16886
interruption	16886
the host	16902
graft interface -LRB- dashed lines in A , C and D -RRB-	16911
graft interface	16911
lines in A , C and D	16935
lines	16935
A , C and D	16944
A modest GFAP-positive astrocytic presence	16957
the border of the transplants	17016
the border	17016
the transplants	17030
few astrocytes being detected in the graft -LRB- arrows in D -RRB-	17052
few astrocytes	17052
the graft -LRB- arrows in D -RRB-	17085
the graft	17085
arrows in D	17096
arrows	17096
D	17106
Blood vessels	17110
the graft -LRB- arrows in B and C -RRB-	17140
the graft	17140
arrows in B and C	17151
arrows	17151
B and C	17161
Some NSFCs	17171
immunoreactivity	17192
BDNF -LRB- arrowheads in yellow ; C -RRB-	17213
BDNF	17213
arrowheads in yellow ; C	17219
arrowheads	17219
yellow ; C	17233
yellow	17233
C	17241
-LRB- E -- F -RRB- Horizontal sections	17245
E -- F	17246
E	17246
F	17248
graft site	17279
Many GFP-labeled cells	17291
MAP-2 -LRB- arrows -RRB-	17338
MAP-2	17338
arrows	17345
numerous MAP-2-positive axons -LRB- arrowheads -RRB-	17375
numerous MAP-2-positive axons	17375
arrowheads	17406
host spinal cord in the lesion site	17423
host spinal cord	17423
the lesion site	17443
interpretation of the references to colour in this figure legend	17465
interpretation	17465
the references to colour in this figure legend	17483
the references	17483
colour in this figure legend	17501
colour	17501
this figure legend	17511
the reader	17531
the web version of this article	17557
the web version	17557
this article	17576
Fig. 2 .	17592
Fig.	17592
2	17597
Photomicrographs of cervical spinal cord sections showing lesion extent , host -- graft integration and host immune response 12 weeks after NSFCs transplantation .	17600
Photomicrographs of cervical spinal cord sections showing lesion extent , host	17600
Photomicrographs	17600
cervical spinal cord sections showing lesion extent , host	17620
cervical spinal cord sections	17620
lesion extent , host	17658
lesion extent	17658
host	17673
graft integration and host immune response 12 weeks after NSFCs transplantation	17678
graft integration and host immune response	17678
12 weeks	17721
NSFCs transplantation	17736
A -- E	17760
A	17760
E	17762
Coronal -LRB- A and B -RRB- and horizontal -LRB- C -- E -RRB- sections	17765
A and B	17774
A	17774
B	17780
C -- E	17799
C	17799
E	17801
host --	17821
host	17821
graft site	17826
toluidine blue to show the extent of the lesion -LRB- dashed lines in A , C and D -RRB- and characteristic cytoarchitecture of NSFCs graft	17855
toluidine blue to show the extent of the lesion -LRB- dashed lines in A , C and D -RRB-	17855
toluidine blue to show the extent of the lesion	17855
toluidine	17855
the extent of the lesion	17878
the extent	17878
the lesion	17892
lines in A , C and D	17911
lines	17911
A , C and D	17920
characteristic cytoarchitecture of NSFCs graft	17936
characteristic cytoarchitecture	17936
NSFCs graft	17971
Numerous engrafted cells	17984
Numerous	17984
cells	18003
the lesion cavity in a longitudinal direction -LRB- C -- E -RRB-	18033
the lesion cavity	18033
a longitudinal direction -LRB- C -- E -RRB-	18054
a longitudinal direction	18054
C -- E	18080
C	18080
E	18082
numerous axons -LRB- arrowheads in E -RRB-	18107
numerous axons	18107
arrowheads in E	18123
arrowheads	18123
E	18137
-LRB- F -- I -RRB- Coronal sections	18141
F -- I	18142
F	18142
I	18144
host	18172
graft site	18177
GFAP -LRB- F and G -RRB- and ED-1 -LRB- H and I -RRB-	18212
GFAP	18212
F and G	18218
F	18218
G	18224
ED-1	18231
H and I	18237
H	18237
I	18243
host immune response	18254
astrocytes -LRB- F and G -RRB- , macrophages	18286
astrocytes -LRB- F and G -RRB-	18286
astrocytes	18286
F and G	18298
F	18298
G	18304
macrophages	18308
microglia -LRB- H and I -RRB- accumulated at the graft -- host interface	18334
microglia -LRB- H and I -RRB-	18334
microglia	18334
H and I	18345
H	18345
I	18351
the graft -- host interface	18369
the graft	18369
host interface	18379
the graft	18411
Fig. 3 .	18423
Fig.	18423
3	18428
Quantitative analysis of the	18431
Quantitative analysis	18431
the	18456
RST in segments	18472
RST	18472
segments	18479
the graft site	18498
The number of regenerated RSTaxons	18514
The number	18514
regenerated RSTaxons	18528
the lower-cervical segments -LRB- p > 0.05 -RRB-	18574
the lower-cervical segments	18574
p > 0.05	18603
p	18603
> 0.05	18604
>	18604
0.05	18605
normal at the upperand middle-thoracic segments -LRB- p < 0.01 -RRB-	18630
normal at the upperand middle-thoracic segments	18630
the upperand	18640
p < 0.01	18679
p	18679
< 0.01	18680
<	18680
0.01	18681
No regenerated axons	18688
the lower-thoracic and lumbar segments	18726
The number of regenerated axons	18766
The number	18766
regenerated axons	18780
the distance	18813
the lesion -- graft site	18831
the lesion	18831
graft site	18842
Fig. 4 .	18855
Fig.	18855
4	18860
Photomicrographs of cross sections of lower-cervical and mid-thoracic segments of the spinal cord illustrating BDA-labeled RST axons .	18863
Photomicrographs	18863
cross sections	18883
lower-cervical and mid-thoracic segments	18901
the spinal cord illustrating BDA-labeled RST axons	18945
the spinal cord	18945
BDA-labeled RST axons	18974
-LRB- A -- D -RRB- The normal RST location and organization at C7 -LRB- A and B -RRB- and T5 -LRB- C and D -RRB- segments in a non-operated control animal .	18997
-LRB- A -- D -RRB- The normal RST location and organization at C7 -LRB- A and B -RRB- and T5 -LRB- C and D -RRB- segments in a non-operated control animal	18997
-LRB- A -- D -RRB- The normal RST location and organization at C7 -LRB- A and B -RRB- and T5 -LRB- C and D -RRB- segments	18997
A -- D -RRB- The normal RST location and organization at C7 -LRB- A and B -RRB- and T5 -LRB- C and D	18998
A -- D -RRB- The normal RST location	18998
A -- D -RRB-	18998
A	18998
D	19000
The normal RST location	19003
organization at C7 -LRB- A and B -RRB- and T5 -LRB- C and D	19031
organization	19031
C7 -LRB- A and B -RRB- and T5 -LRB- C and D	19047
C7	19047
A and B	19051
A	19051
B	19057
T5	19064
a non-operated control animal	19089
Many small and large-caliber RST axons	19120
the dorsolateral funiculus	19173
Axonal branches	19201
lamina V -- VII of the gray matter -LRB- B -RRB-	19233
lamina V	19233
VII of the gray matter -LRB- B -RRB-	19242
VII	19242
the gray matter -LRB- B -RRB-	19249
the gray matter	19249
B	19266
-LRB- E -- H -RRB- Cross sections from a NSFCs-engrafted animal 14 weeks after transplantation demonstrating the presence of regenerating RST axons at the C7 -LRB- E and F -RRB- and T5 -LRB- G and H -RRB- segments , respectively .	19270
-LRB- E -- H -RRB- Cross sections from a NSFCs-engrafted animal 14 weeks after transplantation	19270
-LRB- E -- H -RRB- Cross sections	19270
E -- H	19271
E	19271
H	19273
a NSFCs-engrafted animal 14 weeks	19296
a NSFCs-engrafted animal	19296
14 weeks	19321
transplantation	19336
the presence of regenerating RST axons at the C7 -LRB- E and F -RRB- and T5 -LRB- G and H -RRB- segments , respectively	19366
the presence	19366
RST axons	19395
the C7 -LRB- E and F -RRB- and T5 -LRB- G and H -RRB- segments , respectively	19408
the C7	19408
E and F	19416
E	19416
F	19422
T5 -LRB- G and H -RRB- segments	19429
T5	19429
G and H	19433
G	19433
H	19439
segments	19442
the normal RST at the C7 segment	19478
the normal RST	19478
the C7 segment	19496
numerous smaller-caliber	19512
RST axons	19549
the major part of the lateral funiculus at the corresponding segment -LRB- E and F -RRB-	19595
the major part	19595
the lateral funiculus at the corresponding segment -LRB- E and F -RRB-	19613
the lateral funiculus	19613
the corresponding segment -LRB- E and F -RRB-	19638
the corresponding segment	19638
E and F	19665
E	19665
F	19671
Some axons	19675
collaterals	19691
the gray matter -LRB- arrows in F -RRB-	19708
the gray matter	19708
arrows in F	19725
arrows	19725
F	19735
Axonal branches and terminals	19739
the gray matter including the ventral horn -LRB- outlined area , high magnification is shown in A -RRB-	19785
the gray matter	19785
the ventral horn -LRB- outlined area , high magnification is shown in A -RRB-	19811
the ventral horn	19811
area , high magnification	19838
A	19875
Only a few regenerated RST axons	19879
the dorsolateral funiculus	19926
the T5 segment	19956
the normal RST axons -LRB- G and H -RRB-	19984
the normal RST axons	19984
G and H	20006
G	20006
H	20012
These regenerated axons	20016
they	20078
a rostrocaudal alignment -LRB- H -RRB-	20106
a rostrocaudal alignment	20106
H	20132
Fig. 5 .	20137
Fig.	20137
5	20142
Photomicrographs of the ventral horn of lower-cervical segment showing regenerated synapses of the RST axons 14 weeks after NSFCs transplantation .	20145
Photomicrographs of the ventral horn of lower-cervical segment	20145
Photomicrographs	20145
the ventral horn of lower-cervical segment	20165
the ventral horn	20165
lower-cervical segment	20185
regenerated synapses of the RST axons 14 weeks	20216
regenerated synapses	20216
the RST axons 14 weeks	20240
the RST axons	20240
14 weeks	20254
NSFCs transplantation	20269
-LRB- A and D -RRB- Many BDA-labeled axonal branches and terminals	20292
-LRB- A and D -RRB- Many BDA-labeled axonal branches	20292
-LRB- A and D -RRB-	20292
A	20293
D	20299
Many BDA-labeled axonal branches	20302
terminals	20339
the ventral horn	20375
B	20394
C and E -- F	20396
C and E	20396
F	20404
High magnification	20407
several axonal branches	20439
many varicosities that resemble terminal boutons	20468
many varicosities	20468
terminal boutons	20500
which	20518
motoneuron soma -LRB- stars in E and F -RRB-	20535
motoneuron soma	20535
stars in E and F	20552
stars	20552
E and F	20561
Some	20571
it	20612
they	20630
pre-synaptic boutons -LRB- yellow , indicated by arrowheads in E and F -RRB-	20642
pre-synaptic boutons	20642
yellow , indicated by arrowheads in E and F	20664
yellow	20664
indicated by arrowheads in E and F	20672
indicated	20672
arrowheads in E and F	20685
arrowheads	20685
E and F	20699
interpretation of the references to colour in this figure legend	20714
interpretation	20714
the references to colour in this figure legend	20732
the references	20732
colour in this figure legend	20750
colour	20750
this figure legend	20760
the reader	20780
the web version of this article	20806
the web version	20806
this article	20825
Fig. 6 .	20841
Fig.	20841
6	20846
Electron micrographs of BDA-labeled RST axonal terminals showing reestablishment of synaptic connections with their spinal targets 14 weeks after NSFCs transplantation .	20849
Electron micrographs	20849
BDA-labeled RST axonal terminals showing reestablishment of synaptic connections with their spinal targets 14 weeks after NSFCs transplantation	20873
BDA-labeled RST axonal terminals	20873
reestablishment of synaptic connections with their spinal targets 14 weeks	20914
reestablishment	20914
synaptic connections with their spinal targets 14 weeks	20933
synaptic connections	20933
their spinal targets	20959
14 weeks	20980
NSFCs transplantation	20995
Ultrathin sections	21018
the ventral horn of C6 segment of NSFCs-engrafted -LRB- A -- C -RRB- or lesion-matrix-only -LRB- D -RRB- rats	21056
the ventral horn	21056
C6 segment of NSFCs-engrafted -LRB- A -- C -RRB- or lesion-matrix-only -LRB- D -RRB- rats	21076
C6 segment	21076
NSFCs-engrafted -LRB- A -- C -RRB- or lesion-matrix-only -LRB- D -RRB- rats	21090
A -- C	21107
A	21107
C	21109
D	21135
A and B	21145
BDA-labeled axon terminals establishing synaptic contacts -LRB- arrowheads -RRB- with neuronal soma -LRB- A -RRB- or dendritic branches -LRB- B -RRB-	21162
BDA-labeled axon terminals	21162
synaptic contacts -LRB- arrowheads -RRB- with neuronal soma -LRB- A -RRB- or dendritic branches -LRB- B -RRB-	21202
synaptic contacts -LRB- arrowheads -RRB-	21202
synaptic contacts	21202
arrowheads	21221
neuronal soma -LRB- A -RRB- or dendritic branches -LRB- B -RRB-	21238
neuronal soma	21238
A	21253
dendritic branches	21259
B	21279
-LRB- C -RRB- Morphological and immunocytochemical properties of a BDA-labeled RST axon .	21283
Morphological and immunocytochemical properties	21287
a BDA-labeled RST axon	21338
The appearance of loose and thin myelin sheaths -LRB- arrows -RRB- indicating an incomplete myelin repair .	21362
The appearance of loose and thin myelin sheaths -LRB- arrows -RRB-	21362
The appearance	21362
loose and thin myelin sheaths -LRB- arrows -RRB-	21380
loose and thin myelin sheaths	21380
arrows	21411
an incomplete myelin repair	21430
-LRB- D -RRB- Ultrastructural cytoarchitecture of the ventral horn of C6 segment in a lesion-matrix-only rat .	21459
Ultrastructural cytoarchitecture	21463
the ventral horn	21499
C6 segment	21519
a lesion-matrix-only rat	21533
Neuron-related structures	21559
an astrocyte , spongy extracellular matrix -LRB- asterisk -RRB-	21613
an astrocyte	21613
spongy extracellular matrix -LRB- asterisk -RRB-	21627
spongy extracellular matrix	21627
asterisk	21656
arrows	21694
A , axonal terminal ; As , astrocytic profile ; D ; dendritic profile ; M , myelinated axon ; N , nucleus .	21703
A , axonal terminal ; As , astrocytic profile	21703
axonal terminal	21706
D ; dendritic profile ; M , myelinated axon ; N , nucleus	21747
D ; dendritic profile	21747
D	21747
dendritic profile	21750
M , myelinated axon	21769
M	21769
myelinated axon	21772
N , nucleus	21789
N	21789
nucleus	21792
Fig. 7 .	21802
Fig.	21802
7	21807
Photographs showing forepaw posture of the same lesion-matrix-only -LRB- A -- C -RRB- and NSFCs-engrafted animals -LRB- D -- F -RRB- at different times after engraftment .	21810
Photographs	21810
forepaw posture of the same lesion-matrix-only -LRB- A -- C -RRB- and NSFCs-engrafted animals -LRB- D -- F -RRB-	21830
forepaw posture	21830
the same lesion-matrix-only -LRB- A -- C -RRB- and NSFCs-engrafted animals -LRB- D -- F -RRB-	21849
the same lesion-matrix-only	21849
A -- C	21878
A	21878
C	21880
NSFCs-engrafted animals	21887
D -- F	21912
D	21912
F	21914
different times	21920
engraftment	21942
A and D	21956
A	21956
D	21962
1 week	21965
engraftment	21978
all the digits on the right forepaw -LRB- ipsilateral to the lesion site -RRB-	21991
all the digits on the right forepaw	21991
all the digits	21991
the right forepaw	22009
ipsilateral to the lesion site	22028
ipsilateral	22028
the lesion site	22043
the lesion-matrix-only -LRB- A -RRB-	22075
the NSFCs-engrafted animal -LRB- D -RRB-	22116
the NSFCs-engrafted animal	22116
D	22144
B and E	22149
B	22149
E	22155
6 weeks	22158
engraftment	22172
the digits on the right forepaw	22185
the digits	22185
the right forepaw	22199
further flexed in the same lesion-matrix-only animal -LRB- B -RRB-	22222
further	22222
the same lesion-matrix-only animal -LRB- B -RRB-	22240
the same lesion-matrix-only animal	22240
B	22276
the digits	22284
the same lesion plus engrafted animal -LRB- E -RRB-	22318
the same lesion	22318
animal -LRB- E -RRB-	22349
animal	22349
E	22357
C and F	22362
C	22362
F	22368
1 week	22371
the DLF at right C2	22384
the DLF	22384
right C2	22395
13 weeks after engraftment	22405
13 weeks	22405
engraftment	22420
flexion of the forepaw	22434
flexion	22434
the forepaw	22445
the lesion lesion-matrix-only animal -LRB- C -RRB-	22469
the lesion lesion-matrix-only animal	22469
C	22507
previous forepaw recovery	22517
forelimb flexion in the NSFCsengrafted animal -LRB- F -RRB-	22570
forelimb flexion	22570
the NSFCsengrafted animal -LRB- F -RRB-	22590
the NSFCsengrafted animal	22590
F	22617
Fig. 8 .	22622
Fig.	22622
8	22627
Behavioral analysis of forelimb usage .	22630
Behavioral analysis	22630
forelimb usage	22653
surgery	22676
-LRB- A -RRB- the lesionmatrix - only -LRB- n = 14 -RRB- and -LRB- B -RRB- the lesion plus NSFCs-engrafted animals -LRB- n = 26 -RRB-	22685
-LRB- A -RRB- the lesionmatrix	22685
-LRB- A -RRB-	22685
the lesionmatrix	22689
only -LRB- n = 14 -RRB- and -LRB- B -RRB- the lesion plus NSFCs-engrafted animals -LRB- n = 26 -RRB-	22707
only -LRB- n = 14 -RRB- and -LRB- B -RRB- the lesion	22707
only -LRB- n = 14 -RRB-	22707
only	22707
n	22713
14	22715
B	22724
the lesion	22727
NSFCs-engrafted animals -LRB- n = 26 -RRB-	22743
NSFCs-engrafted animals	22743
n	22768
26	22770
the same percentage of forelimb use	22784
the same percentage	22784
forelimb use	22807
cylinder wall exploration using right	22827
cylinder wall exploration	22827
right	22859
forepaws	22873
both forepaws	22899
Neither group	22929
use of the right forelimb	22953
use	22953
the right forelimb	22960
the first 2 weeks	22986
engraftment	23010
-LRB- A -RRB- No return of function	23023
-LRB- A -RRB- No return	23023
-LRB- A -RRB-	23023
No return	23027
function	23040
the right forelimb of lesion-matrix-only animals	23062
the right forelimb	23062
lesion-matrix-only animals	23084
-LRB- B -RRB- Recovery of use of the right forepaw alone or both forepaws	23112
-LRB- B -RRB-	23112
use of the right forepaw alone or both forepaws	23128
use	23128
the right forepaw alone or both forepaws	23135
the right forepaw alone	23135
both forepaws	23162
the engrafted animals from week 3	23204
the	23204
animals	23218
week 3	23231
This recovery	23239
a plateau between weeks 6 and 7 , which remained constant to week 12	23274
a plateau	23274
weeks 6 and 7 , which remained constant to week 12	23292
weeks 6 and 7	23292
week 12	23334
Fig. 9 .	23344
Fig.	23344
9	23349
Photographs demonstrating the forelimb use 12 weeks after engraftment .	23352
Photographs	23352
the forelimb use	23378
12 weeks	23395
engraftment	23410
-LRB- A -RRB- The right forelimb in lesion-matrix-only animals	23423
-LRB- A -RRB- The right forelimb	23423
-LRB- A -RRB-	23423
The right forelimb	23427
lesion-matrix-only animals	23449
spontaneous vertical exploration -LRB- arrow -RRB-	23519
spontaneous vertical exploration	23519
arrow	23553
-LRB- B -- D -RRB- NSFCs-engrafted animal before , during and after inactivation by muscimol .	23561
-LRB- B -- D -RRB- NSFCs-engrafted animal before , during and after inactivation by muscimol	23561
-LRB- B -- D -RRB- NSFCs-engrafted animal	23561
B -- D	23562
B	23562
D	23564
inactivation by muscimol	23615
inactivation	23615
muscimol	23631
-LRB- B -RRB- Prior to injection of muscimol	23641
-LRB- B -RRB-	23641
injection of muscimol	23654
injection	23654
muscimol	23667
the animal	23677
both paws	23700
the cylinder	23721
the recovered right	23749
motor activity -LRB- arrow -RRB-	23778
motor activity	23778
arrow	23794
injection of muscimol into the left RN	23816
injection	23816
muscimol into the left RN	23829
muscimol	23829
the left RN	23843
the right forelimb	23856
a flexed posture -LRB- arrow -RRB- , indicating that the recovered function was abolished by the drug-induced blockade	23891
a	23891
posture -LRB- arrow -RRB-	23900
posture	23900
arrow	23909
the recovered function	23933
the drug-induced blockade	23973
The animal	24004
the use of the right paw	24024
the use	24024
the right paw	24035
the wall	24069
the effects of the drug	24083
the effects	24083
the drug	24098
48 h	24118
arrow	24130
Fig. 10 .	24139
Fig.	24139
10	24144
Quantitative evaluation of forelimb functional recovery in lesion -- matrix-only and NSFCs-engrafted animals	24148
Quantitative evaluation	24148
forelimb functional recovery in lesion -- matrix-only and NSFCs-engrafted animals	24175
forelimb functional recovery in lesion	24175
forelimb functional recovery	24175
lesion	24207
matrix-only and NSFCs-engrafted animals	24214
irreversible and reversible lesions 12 weeks	24270
irreversible and reversible lesions	24270
12 weeks	24306
engraftment	24321
-LRB- A -RRB- DLF at the right C2 segment	24334
-LRB- A -RRB-	24334
the right C2 segment	24345
little effect on the lesion-matrix-only animals -LRB- n = 6 , p > 0.05 -RRB-	24370
little effect	24370
the lesion-matrix-only animals -LRB- n = 6 , p > 0.05 -RRB-	24387
the lesion-matrix-only animals	24387
n = 6 , p > 0.05	24419
n	24419
= 6 , p > 0.05	24420
= 6 , p >	24420
6 , p	24421
6	24421
p	24424
0.05	24426
contrast	24440
the DLF procedure	24450
the functional recovery	24486
the subgroup of engraftment animals	24513
the subgroup	24513
engraftment animals	24529
up to 4 weeks evaluated -LRB- n = 6 , p < 0.01 -RRB-	24553
up to 4 weeks	24553
n = 6 , p < 0.01	24578
n	24578
= 6 , p < 0.01	24579
= 6 , p <	24579
6 , p	24580
6	24580
p	24583
0.01	24585
-LRB- C -RRB- Injection of saline only into the left RN	24592
-LRB- C -RRB-	24592
saline only into the left RN	24609
saline only	24609
the left RN	24626
forelimb usage of NSFCs-engrafted animals -LRB- n = 6 , p > 0.05 -RRB-	24653
forelimb usage	24653
NSFCs-engrafted animals -LRB- n = 6 , p > 0.05 -RRB-	24671
NSFCs-engrafted animals	24671
n = 6 , p > 0.05	24696
n	24696
= 6 , p > 0.05	24697
= 6 , p >	24697
6 , p	24698
6	24698
p	24701
0.05	24703
-LRB- D -RRB- Injection of muscimol into the left RN of NSFCs-engrafted animals -LRB- n = 6 -RRB-	24710
-LRB- D -RRB- Injection of muscimol into the left RN of NSFCs-engrafted animals	24710
Injection	24714
muscimol into the left RN of NSFCs-engrafted animals	24727
muscimol	24727
the left RN of NSFCs-engrafted animals	24741
the left RN	24741
NSFCs-engrafted animals	24756
n	24781
6	24783
right forelimb dysfunction	24793
inactivation	24827
12 h after injection , p < 0.01	24841
12 h	24841
injection , p < 0.01	24852
injection	24852
p < 0.01	24863
p <	24863
p	24863
0.01	24865
This dysfunction	24872
a 48-h recovery period	24915
Survival and integration of GFP-labeled NSFCs after engraftment into injured host spinal cord Spinal cord tissues from the lesion-matrix-only and lesion plus NSFCs-engrafted groups	24940
Survival and integration	24940
GFP-labeled NSFCs after engraftment into injured host spinal cord Spinal cord tissues from the lesion-matrix-only and lesion plus NSFCs-engrafted groups	24968
GFP-labeled NSFCs	24968
engraftment into injured host spinal cord Spinal cord tissues from the lesion-matrix-only and lesion plus NSFCs-engrafted groups	24992
engraftment into injured host spinal cord Spinal cord tissues from the lesion-matrix-only	24992
engraftment	24992
injured host spinal cord Spinal cord tissues	25009
the lesion-matrix-only	25059
lesion plus NSFCs-engrafted groups	25086
lesion	25086
NSFCs-engrafted groups	25098
lesion extent , the transplant survival , scar tissue formation and the host immune response	25139
lesion extent	25139
the transplant survival	25154
scar tissue formation	25179
the host immune response	25205
The lesion extents	25231
the right dorsolateral and lateral funiculi -LRB- containing the RST -RRB- , and partly regions of the right ventral funiculus and gray matter -LRB- Figs. 1A , and 2A , F and H -RRB-	25259
the right dorsolateral and lateral funiculi -LRB- containing the RST -RRB-	25259
the right dorsolateral and lateral funiculi	25259
the right dorsolateral	25259
lateral funiculi	25286
the RST	25315
partly regions of the right ventral funiculus and gray matter -LRB- Figs. 1A , and 2A , F and H -RRB-	25329
regions	25336
the right ventral funiculus and gray matter -LRB- Figs. 1A , and 2A , F and H -RRB-	25347
the right ventral funiculus and gray matter	25347
Figs. 1A , and 2A , F and H	25392
Figs.	25392
1A	25398
2A , F and H	25406
NSFCs	25430
the lesion cavity	25454
the margins of the transected cord without interruption	25488
the margins	25488
the transected cord without interruption	25503
the	25503
cord	25518
interruption	25531
cysts or scar tissue	25547
the graft -- host interface -LRB- Figs. 1A -- D and 2A -- E -RRB-	25571
the graft	25571
host interface	25581
Figs. 1A	25597
D and 2A -- E	25606
D and 2A	25606
E	25615
A few cells	25619
BDNF -LRB- Fig. 1C -RRB-	25659
BDNF	25659
Fig. 1C	25665
Most of the engrafted NSFCs	25675
Most	25675
the engrafted NSFCs	25683
the	25683
NSFCs	25697
mature neuronal makers such as MAP-2 -LRB- microtubule-associated protein -RRB-	25725
mature neuronal makers	25725
MAP-2 -LRB- microtubule-associated protein -RRB-	25756
MAP-2	25756
microtubule-associated protein	25763
numerous many MAP-2-positive axons from host spinal cord at the graft site -LRB- Figs. 1E and F -RRB-	25817
numerous many MAP-2-positive axons	25817
host spinal cord at the graft site -LRB- Figs. 1E and F -RRB-	25857
host spinal cord	25857
the graft site -LRB- Figs. 1E and F -RRB-	25877
the graft site	25877
Figs. 1E and F	25893
Figs. 1E	25893
F	25906
the host immune response	25926
additional immunocytochemical studies	25952
anti-GFAP antibody	26012
astrocytes and ED-1 antibody	26043
activated macrophages and microglia	26084
These studies	26121
astrocytes -LRB- Figs. 1D and 2F and G -RRB- , macrophages and activated microglia -LRB- Figs. 2H and I -RRB- at the graft -- host interface ,	26148
astrocytes	26148
Figs. 1D and 2F and G	26160
Figs. 1D	26160
2F and G	26173
macrophages and activated microglia -LRB- Figs. 2H and I -RRB- at the graft -- host interface	26184
macrophages and activated microglia -LRB- Figs. 2H and I -RRB-	26184
macrophages and activated microglia	26184
macrophages	26184
activated microglia	26200
Figs. 2H and I	26221
the graft -- host interface	26240
the graft	26240
host interface	26250
the graft	26277
The good graft survival and mild immune responses	26288
The good graft survival	26288
mild immune responses	26316
the efficient cyclosporine immunosuppression protocols	26357
the inhibition of inflammation	26419
the inhibition	26419
inflammation	26437
penicillin	26455
The engrafted NSFCs promote axotomized RST axonal regeneration and reestablish synaptic connections with their spinal targets The effect of NSFCs-engraftment on axotomized RST axonal regeneration	26467
NSFCs	26481
RST axonal regeneration	26506
synaptic connections	26546
their spinal targets	26572
The effect of NSFCs-engraftment	26593
The effect	26593
NSFCs-engraftment	26607
RST axonal regeneration	26639
the previous data -LRB- Xiao et al. , 2005 -RRB-	26678
the previous data	26678
Xiao	26697
et al. , 2005	26702
et al.	26702
2005	26710
the repeated description	26735
the present study	26761
the quantitative analysis of the distance that RST axons regenerated into segments caudal to the lesion -- graft site	26791
the quantitative analysis	26791
the distance that RST axons regenerated into segments caudal to the lesion -- graft site	26820
the distance	26820
RST axons	26838
segments caudal to the lesion -- graft site	26865
segments	26865
the lesion -- graft site	26884
the lesion	26884
graft site	26895
all lesion-matrix-only animals	26910
no BDA-labeled RST axons	26942
the dorsolateral funiculus of the host spinal cord caudal	26984
the dorsolateral funiculus	26984
the host spinal cord caudal	27014
the lesion	27045
all eight BDA tracing NSFCs-engrafted animals	27060
all eight BDA	27060
NSFCs-engrafted animals	27082
regenerated axons	27107
caudal	27136
the lesion site	27146
five animals	27166
BDA-labeled RST axons	27180
mid-thoracic segments -LRB- T5 -- 6 -RRB- , 4 -- 8 segments caudal	27215
mid-thoracic segments -LRB- T5 -- 6 -RRB-	27215
mid-thoracic segments	27215
T5 -- 6	27238
T5	27238
6	27241
4 -- 8 segments caudal	27245
4	27245
8 segments	27247
the transplant	27268
Quantitative analysis	27284
regenerated RST axons	27315
number the farther caudal to the graft -LRB- Fig. 3 -RRB-	27350
number the farther caudal to the graft	27350
number	27350
the graft	27379
Fig. 3	27390
the C6 -- 7 segments of transplanted animals	27402
the C6	27402
7 segments of transplanted animals	27409
7 segments	27409
transplanted animals	27423
the number of regenerated RST axons	27445
the number	27445
regenerated RST axons	27459
RST axons	27504
the T4 -- 5 segments	27518
the T4	27518
5 segments	27525
fewer regenerated axons	27537
comparison	27574
the controls -LRB- Fig. 4 -RRB-	27588
the controls	27588
Fig. 4	27602
the potential of regenerated RST axons	27623
the potential	27623
regenerated RST axons	27640
synaptic connections	27677
their spinal targets	27703
the distribution of BDA-labeled collaterals and terminals in the gray matter	27725
the distribution	27725
BDA-labeled collaterals and terminals in the gray matter	27745
BDA-labeled collaterals and terminals	27745
the gray matter	27786
segments caudal to the lesion -- graft site	27818
segments	27818
the lesion -- graft site	27837
the lesion	27837
graft site	27848
the caudal segments adjacent to the lesion -- graft site	27863
the caudal segments	27863
the lesion -- graft site	27895
the lesion	27895
graft site	27906
many collaterals	27918
V -- VII of the ipsilateral gray matter -LRB- Figs. 4C and D -RRB-	27971
V	27971
VII of the ipsilateral gray matter -LRB- Figs. 4C and D -RRB-	27973
VII	27973
the ipsilateral gray matter -LRB- Figs. 4C and D -RRB-	27980
the ipsilateral gray matter	27980
Figs. 4C and D	28009
Figs. 4C	28009
D	28022
Many BDA-labeled branches	28026
laminae V -- VII , with some terminal -- bouton-like structures in close apposition	28066
laminae V -- VII , with some terminal -- bouton-like structures	28066
VII , with some	28076
VII	28076
some	28086
close apposition	28127
interneurons	28147
the C6 -- C7 segments	28164
the C6	28164
C7 segments	28171
many axonal branches and terminals	28184
many axonal branches	28184
terminals	28209
the ventral horn -LRB- laminae VIII -- IX -RRB- -LRB- Fig. 5 -RRB-	28245
the ventral horn -LRB- laminae VIII -- IX -RRB-	28245
the ventral horn	28245
laminae VIII -- IX	28263
laminae VIII	28263
IX	28276
Fig. 5	28281
biotin -- FITC/synapsin double-labeled sections	28293
biotin	28293
FITC/synapsin double-labeled sections	28300
FITC/synapsin	28300
double-labeled sections	28314
some axonal branches	28339
the somata of motoneurons	28371
the somata	28371
motoneurons	28385
presynaptic boutons -LRB- Figs. 5E -- F -RRB-	28408
presynaptic boutons	28408
Figs. 5E -- F	28429
Figs. 5E	28429
F	28438
the more caudal segments	28445
fewer BDA-labeled collaterals	28471
the mid-thoracic level	28516
no collaterals	28540
the gray matter	28568
a few BDA-labeled RST axons	28594
the dorsolateral funiculus -LRB- Figs. 4G and H -RRB-	28644
the dorsolateral funiculus	28644
Figs. 4G and H	28672
Figs. 4G	28672
H	28685
Ultrastructural analysis	28689
NSFCs-engraftment	28731
the RST axons ' regeneration and reestablishment of synaptic connections	28758
the RST axons ' regeneration and reestablishment	28758
the RST axons '	28758
synaptic connections	28809
ventral horn neurons of the distal cervical spinal cord	28835
ventral horn neurons	28835
the distal cervical spinal cord	28859
BDA-labeled terminals	28892
synapses on neuronal soma or dendrites	28944
synapses	28944
neuronal soma or dendrites	28956
the ventral horn of C6 segment of engrafted rats -LRB- Figs. 6A and B -RRB-	28986
the ventral horn	28986
C6 segment of engrafted rats -LRB- Figs. 6A and B -RRB-	29006
C6 segment	29006
rats -LRB- Figs. 6A and B -RRB-	29030
rats	29030
Figs. 6A and B	29036
Figs. 6A	29036
B	29049
remyelination	29068
place	29087
all BDA-labeled axons	29096
myelin repair	29128
incomplete , which was characterized by the loose and thin myelin sheaths -LRB- Fig. 6C -RRB-	29149
incomplete	29149
the loose and thin myelin sheaths -LRB- Fig. 6C -RRB-	29188
the loose and thin myelin sheaths	29188
Fig. 6C	29223
The above regenerated synapses	29233
the C6 -- 7 segments of four NSFCs-engrafted animals used for electron microscopic examination	29288
the C6	29288
7 segments of four NSFCs-engrafted animals used for electron microscopic examination	29295
7 segments	29295
four NSFCs-engrafted animals used for electron microscopic examination	29309
four NSFCs-engrafted animals	29309
electron microscopic examination	29347
contrast	29384
no BDA-labeled axons or terminals	29394
no BDA-labeled axons	29394
terminals	29418
the ventral horn of C6 segment	29442
the ventral horn	29442
C6 segment	29462
lesion-matrix-only animals	29476
astrocytes	29518
masses of filamentous or extracellular matrix -LRB- Fig. 6D -RRB-	29530
masses	29530
filamentous or extracellular matrix -LRB- Fig. 6D -RRB-	29540
filamentous or extracellular matrix	29540
Fig. 6D	29577
NSFCs	29597
functional recovery Forelimb	29611
different times	29668
engraftment	29690
1 week	29703
engraftment	29716
prominent deficits	29729
elbow and digit extension of the right forelimb in both lesion-matrix-only -LRB- Fig. 7A -RRB- and NSFCs-engrafted groups -LRB- Fig. 7D -RRB-	29761
elbow and digit extension	29761
the right forelimb in both lesion-matrix-only -LRB- Fig. 7A -RRB- and NSFCs-engrafted groups -LRB- Fig. 7D -RRB-	29790
the right forelimb	29790
both lesion-matrix-only -LRB- Fig. 7A -RRB- and NSFCs-engrafted groups	29812
lesion-matrix-only -LRB- Fig. 7A -RRB-	29817
lesion-matrix-only	29817
Fig. 7A	29837
NSFCs-engrafted groups	29850
Fig. 7D	29874
This forepaw flexion	29884
12 weeks	29925
all lesion-matrix-only animals -LRB- Fig. 7B -RRB-	29937
all lesion-matrix-only animals	29937
Fig. 7B	29969
contrast	29982
partial reextension of proximal and distal forelimb	29992
partial reextension	29992
proximal and distal forelimb	30015
some NSFCs-engrafted animals early as 2 weeks	30056
some NSFCs-engrafted animals	30056
2 weeks	30094
engraftment	30108
the 6th week after NSFCs engraftment	30134
the 6th week	30134
NSFCs engraftment	30153
full extension of the right forepaw	30172
full extension	30172
the right forepaw	30190
73 % -LRB- n = 19 -RRB- of the animals -LRB- total n = 26 -RRB- evaluated -LRB- Fig. 7E -RRB-	30220
73 % -LRB- n = 19 -RRB-	30220
73 %	30220
n	30225
19	30227
the animals -LRB- total n = 26 -RRB- evaluated	30234
the animals	30234
total n	30247
26	30255
Fig. 7E	30270
Seven engrafted animals	30280
Seven	30280
animals	30296
considerable improvement	30319
elbow and digit extension	30347
the end of the 12th week	30376
the end	30376
the 12th week	30387
Weekly observation of spontaneous vertical exploration	30402
Weekly observation	30402
spontaneous vertical exploration	30424
corresponding functional recovery	30478
the 1st week after transplantation	30520
the 1st week	30520
transplantation	30539
animals in both groups	30556
animals	30556
both groups	30567
95 %	30606
their left forelimb , rarely -LRB- 5 % -RRB-	30614
their left forelimb , rarely	30614
their left forelimb	30614
5 %	30643
both forelimbs	30653
the wall -LRB- Fig. 8 -RRB-	30679
the wall	30679
Fig. 8	30689
No return of function	30698
No return	30698
function	30711
any of the lesion-matrix-only animals through the 12 - week observation period -LRB- Figs. 8A and 9A -RRB-	30733
any	30733
the lesion-matrix-only animals through the 12 - week observation period -LRB- Figs. 8A and 9A -RRB-	30740
the lesion-matrix-only animals through the 12 - week observation period	30740
lesion-matrix-only animals	30744
the 12	30779
Figs. 8A and 9A	30812
Figs. 8A	30812
9A	30825
the NSFCsengrafted animals	30838
the use of both forepaws	30866
the use	30866
both forepaws	30877
28 %	30919
the 2nd week	30926
limited functional recovery -LRB- Fig. 8B -RRB-	30951
limited functional recovery	30951
Fig. 8B	30980
the 3rd week on	30995
the 3rd week	30995
use of the right forelimb alone -LRB- 3 % -RRB-	31012
use	31012
the right forelimb alone -LRB- 3 % -RRB-	31019
the right forelimb alone	31019
the right forelimb	31019
3 %	31045
the NSFCs-engrafted animals -LRB- Fig. 8B -RRB-	31062
the NSFCs-engrafted animals	31062
Fig. 8B	31091
the end of 6 weeks	31104
the end	31104
6 weeks	31115
the use of the right forepaw alone and both forepaws	31124
the use	31124
the right forepaw alone and both forepaws	31135
the right forepaw alone	31135
both forepaws	31163
80 % , which closely approximated the preoperative level -LRB- 90 % -RRB-	31196
80 %	31196
the preoperative level -LRB- 90 % -RRB-	31228
the preoperative level	31228
90 %	31252
This level of recovery	31258
This level	31258
recovery	31272
the remaining observation period -LRB- Figs. 8B and 9B -RRB-	31304
the remaining observation period	31304
Figs. 8B and 9B	31338
Figs. 8B	31338
9B	31351
recovery in NSFCs-engrafted animals	31365
recovery	31365
NSFCs-engrafted animals	31377
irreversible and reversible lesions of regenerated RST	31418
irreversible and reversible lesions	31418
regenerated RST	31457
the recovery of forelimb function	31496
the recovery	31496
forelimb function	31512
NSFCs-engrafted animals	31539
the RST axonal regeneration and reinnervation	31581
the RST axonal regeneration	31581
reinnervation	31613
the regenerated RST axons	31628
a second DLF	31683
the right C2 segment	31699
injection of muscimol	31746
injection	31746
muscimol	31759
the left RN	31773
The second DLF	31786
little effect on the flexion of the forepaw and forelimb usage in the lesion-matrix-only animals -LRB- p > 0.05 , Figs. 7C and 10A -RRB-	31805
little effect	31805
the flexion of the forepaw and forelimb usage in the lesion-matrix-only animals -LRB- p > 0.05 , Figs. 7C and 10A -RRB-	31822
the flexion	31822
the forepaw and forelimb usage in the lesion-matrix-only animals -LRB- p > 0.05 , Figs. 7C and 10A -RRB-	31837
the forepaw and forelimb usage	31837
the lesion-matrix-only animals -LRB- p > 0.05 , Figs. 7C and 10A -RRB-	31871
the lesion-matrix-only animals	31871
p	31903
> 0.05 , Figs. 7C and 10A	31904
>	31904
0.05	31905
Figs. 7C and 10A	31911
all six engrafted animals , the restored extension of the forepaw and recovered forelimb	31937
all six	31937
animals , the restored extension of the forepaw	31955
animals	31955
the restored extension of the forepaw	31964
the restored extension	31964
the forepaw	31990
use	32025
up to 4 weeks	32059
the operation -LRB- p < 0.01 , Figs. 7F and 10B -RRB-	32079
the operation	32079
p	32094
< 0.01 , Figs. 7F and 10B	32095
<	32095
0.01	32096
Figs. 7F and 10B	32102
the prominent deficits in elbow and digit extension of the right forelimb	32132
the prominent deficits	32132
elbow and digit extension of the right forelimb	32158
elbow and digit extension	32158
the right forelimb	32187
following injection of the neural blocking agent muscimol into the magnocellular portion of the left RN of six NSFCs-engrafted animals	32216
following injection	32216
the neural blocking agent muscimol into the magnocellular portion of the left RN of six NSFCs-engrafted animals	32239
the neural	32239
agent muscimol	32259
the magnocellular portion of the left RN of six NSFCs-engrafted animals	32279
the magnocellular portion	32279
the left RN of six NSFCs-engrafted animals	32308
the left RN	32308
six NSFCs-engrafted animals	32323
Flexion of the right forelimb	32352
Flexion	32352
the right forelimb	32363
the animals	32406
This dysfunction	32447
18 -- 24 h -LRB- Fig. 9C -RRB-	32478
18	32478
24 h -LRB- Fig. 9C -RRB-	32481
Fig. 9C	32487
normal posture	32506
Fig. 9D	32541
Forelimb use by the NSFCs - engrafted animals receiving saline alone or muscimol	32551
Forelimb use	32551
the NSFCs - engrafted animals receiving saline alone or muscimol	32567
the NSFCs	32567
animals	32588
saline alone or muscimol	32606
saline alone	32606
muscimol	32622
recovery	32667
the drug -LRB- Figs. 10C and D -RRB-	32681
the drug	32681
Figs. 10C and D	32691
Figs. 10C	32691
D	32705
Behavioral data	32709
the animals	32743
right forelimb use	32760
12 h	32783
injection of muscimol -LRB- p < 0.01 -RRB-	32794
injection	32794
muscimol -LRB- p < 0.01 -RRB-	32807
muscimol	32807
p < 0.01	32817
p	32817
< 0.01	32818
<	32818
0.01	32819
48 h after the injection	32829
48 h	32829
the injection	32840
pre-injection levels of function -LRB- p > 0.05 -RRB- -LRB- Fig. 10D -RRB-	32872
pre-injection levels	32872
function -LRB- p > 0.05 -RRB- -LRB- Fig. 10D -RRB-	32896
function -LRB- p > 0.05 -RRB-	32896
function	32896
p > 0.05	32906
p	32906
> 0.05	32907
>	32907
0.05	32908
Fig. 10D	32915
Similar results	32926
the animals	32961
an additional injection -LRB- p > 0.05 -RRB-	32982
an additional injection	32982
p > 0.05	33007
p	33007
> 0.05	33008
>	33008
0.05	33009
Six NSFCsengrafted animals that received saline injections to the RN	33016
Six NSFCsengrafted animals	33016
saline injections	33057
the RN	33078
deficits of forelimb posture -LRB- p > 0.05 -RRB-	33101
deficits	33101
forelimb posture -LRB- p > 0.05 -RRB-	33113
forelimb posture	33113
p > 0.05	33131
p	33131
> 0.05	33132
>	33132
0.05	33133
neuronal inactivation , not a mechanical or osmotic effect of drug injection ,	33153
neuronal inactivation	33153
a mechanical or osmotic effect of drug injection	33180
a mechanical or osmotic effect	33180
drug injection	33214
the cause of the temporary effect -LRB- Fig. 10C -RRB-	33234
the cause	33234
the temporary effect -LRB- Fig. 10C -RRB-	33247
the temporary effect	33247
Fig. 10C	33269
Discussion The rat RST	33281
Discussion	33281
The rat RST	33292
the magnocellular part of the caudal RN	33317
the magnocellular part	33317
the caudal RN	33343
the brain stem	33360
nearly completely -LRB- 99 % -RRB-	33389
nearly completely	33389
99 %	33408
the dorsolateral aspect of the spinal cord -LRB- Liu et al. , 1999 ; Kwon et al. , 2002 -RRB-	33430
the dorsolateral aspect	33430
the spinal cord -LRB- Liu et al. , 1999 ; Kwon et al. , 2002 -RRB-	33457
the spinal cord	33457
Liu	33474
et al. , 1999 ; Kwon et al. , 2002	33478
et al.	33478
1999 ; Kwon et al.	33486
1999	33486
Kwon et al.	33492
Kwon	33492
et al.	33497
2002	33505
This lateral position	33512
the entire RST	33540
a partial hemisection , in which the lateral funiculus and part of the ventral white matter are ablated	33577
a partial hemisection	33577
the lateral funiculus and part of the ventral white matter	33609
the lateral funiculus and part	33609
the ventral white matter	33643
the rat	33684
the rubrospinal system	33693
the control of skilled limb movement , particularly of the forelimbs	33747
the control	33747
skilled limb movement , particularly	33762
skilled limb movement	33762
the forelimbs	33801
Muir and Whishaw	33816
2000	33834
the adult PCHX rat model	33846
the effect of cellular engrafts	33899
the effect	33899
cellular engrafts	33913
regeneration of rubrospinal axons and recovery of forelimb function -LRB- Liu et al. , 1999 ; Kim et al. , 2001 ; Ruitenberg et al. , 2003 -RRB-	33934
regeneration of rubrospinal axons	33934
regeneration	33934
rubrospinal axons	33950
recovery of forelimb function -LRB- Liu et al. , 1999 ; Kim et al. , 2001 ; Ruitenberg et al. , 2003 -RRB-	33972
recovery	33972
forelimb function -LRB- Liu et al. , 1999 ; Kim et al. , 2001 ; Ruitenberg et al. , 2003 -RRB-	33984
forelimb function	33984
Liu et al. , 1999 ; Kim et al. , 2001 ; Ruitenberg et al. , 2003	34003
Liu	34003
et al. , 1999 ; Kim et al. , 2001 ; Ruitenberg et al. , 2003	34007
et al. , 1999	34007
et al.	34007
1999	34015
Kim et al. , 2001	34021
Kim	34021
et al. , 2001	34025
et al.	34025
2001	34033
Ruitenberg et al. , 2003	34039
Ruitenberg	34039
et al. , 2003	34050
et al.	34050
2003	34058
a previous study -LRB- Xiao et al. , 2005 -RRB- and for this study	34069
a previous study -LRB- Xiao et al. , 2005 -RRB-	34069
a previous study	34069
Xiao	34087
et al. , 2005	34092
et al.	34092
2005	34100
for this study	34110
we	34126
this model to explore the potential of human olfactory neural progenitors for repair of the injured spinal cord	34138
the potential of human olfactory neural progenitors for repair of the injured spinal cord	34160
the potential	34160
human olfactory neural progenitors for repair of the injured spinal cord	34177
human olfactory neural progenitors	34177
repair of the injured spinal cord	34216
repair	34216
the injured spinal cord	34226
our results	34264
engraftment of human adult olfactory-derived NSFCs	34332
engraftment	34332
human adult olfactory-derived NSFCs	34347
regeneration and reinnervation of adult rat RST and forelimb functional recovery	34391
regeneration and reinnervation	34391
adult rat RST and forelimb functional recovery	34425
NSFCs	34483
RST axonal regeneration and reinnervation BDA	34497
RST axonal regeneration	34497
reinnervation BDA	34525
NSFCs	34591
RST	34605
axonal regeneration and reestablishment of synaptic connections with host spinal targets	34609
axonal regeneration and reestablishment	34609
synaptic connections with host spinal targets	34652
synaptic connections	34652
host spinal targets	34678
Many regenerated axons	34699
laminae V -- VII , with terminal --	34739
laminae V	34739
VII	34749
bouton-like structures	34768
interneurons , which are normal RST targets in the spinal cord -LRB- Antal et al. , 1992 -RRB-	34800
interneurons	34800
normal RST targets in the spinal cord -LRB- Antal et al. , 1992 -RRB-	34824
normal RST targets	34824
the spinal cord -LRB- Antal et al. , 1992 -RRB-	34846
the spinal cord	34846
Antal	34863
et al. , 1992	34869
et al.	34869
1992	34877
segments C6 -- 7	34887
segments C6	34887
7	34899
many regenerating axonal branches and terminals	34902
many regenerating axonal branches	34902
terminals	34940
the ventral horn -LRB- laminae VIII -- IX -RRB-	34972
the ventral horn	34972
laminae VIII -- IX	34990
laminae VIII	34990
IX	35003
synaptic connections	35015
motoneuron soma	35041
The regenerated synapses	35058
the ultrastructural examination , which revealed BDA-labeled terminals made synaptic contacts with the cell bodies or dendrites of ventral horn neurons at C6	35109
the ultrastructural examination	35109
BDA-labeled terminals	35157
synaptic contacts	35184
the cell bodies or dendrites of ventral horn neurons	35207
the cell bodies or dendrites	35207
ventral horn neurons	35239
C6	35263
7 segments	35266
These results	35278
the previous reports	35312
some RST terminals	35338
synapses with distinct motoneurons	35362
synapses	35362
distinct motoneurons	35376
lower cervical segments , which perform specific , preferential role in distal forelimb muscle control -LRB- Kuchler et al. , 2002 -RRB-	35400
lower cervical segments	35400
specific , preferential role in distal forelimb muscle control -LRB- Kuchler et al. , 2002 -RRB-	35439
specific , preferential role	35439
distal forelimb muscle control -LRB- Kuchler et al. , 2002 -RRB-	35470
distal forelimb muscle control	35470
Kuchler	35502
et al. , 2002	35510
et al.	35510
2002	35518
it	35530
NSFCs	35541
regeneration	35566
the formation of synaptic contacts , which is an important issue in spinal cord repair strategies -LRB- Yakovleff et al. , 1995 -RRB-	35599
the formation	35599
synaptic contacts , which is an important issue in spinal cord repair strategies -LRB- Yakovleff et al. , 1995 -RRB-	35616
synaptic contacts	35616
an important issue in spinal cord repair strategies -LRB- Yakovleff et al. , 1995 -RRB-	35644
an important issue	35644
spinal cord repair strategies -LRB- Yakovleff et al. , 1995 -RRB-	35666
spinal cord repair strategies	35666
Yakovleff	35697
et al. , 1995	35707
et al.	35707
1995	35715
our knowledge	35725
it	35740
the first report	35746
RST axons	35768
synapses	35802
host spinal targets in current cell transplantation therapies for spinal cord regeneration	35816
host spinal targets	35816
current cell transplantation therapies for spinal cord regeneration	35839
current cell transplantation therapies	35839
spinal cord regeneration	35882
Regeneration and reinnervation by the RST axons	35908
Regeneration and reinnervation	35908
the RST axons	35942
the distance from the graft	35978
the distance	35978
the graft	35996
No regenerated RST axons	36007
No	36007
RST axons	36022
the lower-thoracic or lumbar segments , perhaps due to the inhibitory environment in the adult spinal cord which hinders regeneration following cord injury -LRB- Beattie et al. , 1997 ; Geller and Fawcett , 2002 -RRB-	36045
the lower-thoracic or lumbar segments	36045
the inhibitory environment in the adult spinal cord which hinders regeneration following cord injury -LRB- Beattie et al. , 1997 ; Geller and Fawcett , 2002 -RRB-	36099
the inhibitory environment	36099
the adult spinal cord which hinders regeneration following cord injury -LRB- Beattie et al. , 1997 ; Geller and Fawcett , 2002 -RRB-	36129
the adult spinal cord	36129
regeneration following cord injury	36165
regeneration	36165
cord injury	36188
Beattie	36201
et al. , 1997 ; Geller and Fawcett , 2002	36209
et al.	36209
1997 ; Geller and Fawcett	36217
1997	36217
Geller and Fawcett	36223
2002	36243
This	36250
the importance of the observed regeneration	36273
the importance	36273
the observed regeneration	36291
the future	36321
autologous engraftment of NSFCs	36332
autologous engraftment	36332
NSFCs	36358
a useful strategy for patients with upper cervical SCI	36373
a useful strategy	36373
patients with upper cervical SCI	36395
patients	36395
upper cervical SCI	36409
only limited regeneration	36438
several segments of axonal regeneration and reinnervation	36472
several segments	36472
axonal regeneration and reinnervation	36492
patients	36541
a respirator , or gain limited mobility -LRB- Kwon and Tetzlaff , 2001 -RRB-	36566
a respirator	36566
gain limited mobility -LRB- Kwon and Tetzlaff , 2001 -RRB-	36583
gain limited mobility	36583
Kwon and Tetzlaff , 2001	36606
Kwon	36606
Tetzlaff , 2001	36615
Tetzlaff	36615
2001	36625
addition	36635
we	36645
this reinnervation	36677
regenerated RST axons	36712
the plasticity of spared one	36741
the plasticity	36741
one	36766
The interpretations	36771
the histological analysis	36815
the right dorsolateral and lateral funiculi	36861
the right dorsolateral	36861
lateral funiculi	36888
the ventral white matter	36935
the PCHX -LRB- Figs. 1A and 2A , F and H -RRB-	36992
the PCHX	36992
Figs. 1A and 2A , F and H	37002
Figs. 1A	37002
2A , F and H	37015
This lesion extent	37029
the RST -LRB- Liu et al. , 1999 -RRB- , which was further confirmed by anterograde tracing evidence that no BDA-labeled axons were detected caudal to the lesion site in all lesion-matrix-only animals in the present study as well as in our previous investigation -LRB- Xiao et al. , 2005 -RRB-	37071
the RST -LRB- Liu et al. , 1999 -RRB-	37071
the RST	37071
Liu	37080
et al. , 1999	37084
et al.	37084
1999	37092
anterograde	37130
evidence	37150
no BDA-labeled axons	37164
the lesion site	37209
all lesion-matrix-only animals in the present study	37228
all lesion-matrix-only animals	37228
the present study	37262
our previous investigation -LRB- Xiao et al. , 2005 -RRB-	37294
our previous investigation	37294
Xiao	37322
et al. , 2005	37327
et al.	37327
2005	37335
the almost complete -LRB- 99 % -RRB- contralateral trajectory of RST	37372
the almost complete -LRB- 99 % -RRB- contralateral trajectory	37372
99 %	37393
RST	37426
an unambiguous interpretation of the anatomical tracing results following a unilateral axotomy -LRB- Kwon et al. , 2002 -RRB- , in contrast to other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37437
an unambiguous interpretation	37437
the anatomical tracing results following a unilateral axotomy -LRB- Kwon et al. , 2002 -RRB- , in contrast to other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37470
the anatomical	37470
results following a unilateral axotomy -LRB- Kwon et al. , 2002 -RRB- , in contrast to other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37493
results	37493
a unilateral axotomy -LRB- Kwon et al. , 2002 -RRB- , in contrast to other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37511
a unilateral axotomy	37511
Kwon	37533
et al. , 2002	37538
et al.	37538
2002	37546
contrast to other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37556
contrast	37556
other descending pathways in which spared axons and collateral sprouting may complicate the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37568
other descending pathways	37568
axons and collateral sprouting	37610
axons and collateral	37610
the interpretation -LRB- Waldron and Gwyn , 1969 ; Tracey , 1995 -RRB-	37656
the interpretation	37656
Waldron and Gwyn , 1969 ; Tracey , 1995	37676
Waldron and Gwyn	37676
1969 ; Tracey	37694
1969	37694
Tracey	37700
1995	37708
the recovery of forelimb function in NSFCs-engrafted animals completely abolished by a second DLF at C2	37724
the recovery	37724
forelimb function in NSFCs-engrafted animals completely abolished by a second DLF at C2	37740
forelimb function	37740
NSFCs-engrafted animals completely abolished by a second DLF at C2	37761
NSFCs-engrafted animals	37761
a second DLF at C2	37809
a second DLF	37809
C2	37825
functional recovery	37855
due to regeneration of severed neurites rather than reorganization of spared axons	37878
due to regeneration of severed neurites	37878
regeneration of severed	37885
regeneration	37885
reorganization of spared axons	37930
reorganization	37930
spared axons	37948
Functional recovery	37962
RST	37998
axonal regeneration and reinnervation The enhanced function observed in NSFCs-engrafted animals correlates with RST axonal regeneration and reinnervation	38002
axonal regeneration and reinnervation	38002
The enhanced function observed in NSFCs-engrafted animals	38040
The enhanced function	38040
NSFCs-engrafted animals	38074
RST axonal regeneration and reinnervation	38114
RST axonal regeneration	38114
reinnervation	38142
Behavioral studies	38157
the NSFCs-engrafted animals	38194
use of their forelimb	38250
use	38250
their forelimb	38257
the side of the lesion at 2 weeks	38275
the side	38275
the lesion at 2 weeks	38287
the lesion	38287
2 weeks	38301
engraftment	38315
The improvement	38328
the 6th week	38360
it	38379
observation	38397
week 12	38418
The progress of recovery	38427
The progress	38427
recovery	38443
the distance of RST axonal regeneration	38465
the distance	38465
RST axonal regeneration	38481
agreement	38516
previous data that the RST axons regenerated at a rate of 1 -- 1.5 mm/day during the first month after transplantation -LRB- Liu et al. , 1999 -RRB-	38531
previous data	38531
the RST axons	38550
a rate of 1 -- 1.5 mm/day during the first month	38579
a rate of 1	38579
a rate	38579
1	38589
1.5 mm/day during the first month	38591
1.5 mm/day	38591
the first month	38609
transplantation	38631
Liu	38648
et al. , 1999	38652
et al.	38652
1999	38660
it	38667
about 10 -- 14 days for RST axons	38676
about 10	38676
14 days for RST axons	38685
14 days	38685
RST axons	38697
the NSFCs graft	38721
cervical segments	38747
3 -- 5 segments proximal to the host --	38771
3	38771
5 segments	38773
the host	38796
graft interface	38806
This region of the spinal cord	38823
This region	38823
the spinal cord	38838
the distal joint of the forelimb -LRB- McKenna et al. , 2000 ; Kuchler et al. , 2002 -RRB-	38865
the distal joint	38865
the forelimb -LRB- McKenna et al. , 2000 ; Kuchler et al. , 2002 -RRB-	38885
the forelimb	38885
McKenna	38899
et al. , 2000 ; Kuchler et al. , 2002	38907
et al.	38907
2000 ; Kuchler et al.	38915
2000	38915
Kuchler et al.	38921
Kuchler	38921
et al.	38929
2002	38937
the first several weeks after engraftment	38957
the first several weeks	38957
engraftment	38987
RST axonal regeneration and recovery of forelimb function	39015
RST axonal regeneration	39015
recovery of forelimb function	39043
recovery	39043
forelimb function	39055
spinal cord injury	39079
Similar relationships	39099
studies	39135
transplanted BDNF engineered fibroblasts in a cervical cord lesion -LRB- Liu et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003 -RRB-	39148
transplanted BDNF engineered fibroblasts	39148
a cervical cord lesion -LRB- Liu et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003 -RRB-	39192
a cervical cord lesion	39192
Liu et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003	39216
Liu	39216
et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003	39220
et al. , 1999	39220
et al.	39220
1999	39228
Jin et al. , 2002	39234
Jin	39234
et al. , 2002	39238
et al.	39238
2002	39246
Shumsky et al. , 2003	39252
Shumsky	39252
et al. , 2003	39260
et al.	39260
2003	39268
The extent of RST axonal regeneration after a 6-week delay	39275
The extent	39275
RST axonal regeneration after a 6-week delay	39289
RST axonal regeneration	39289
a 6-week delay	39319
transplantation	39343
an acute transplant	39388
a 4-week delay -LRB- Liu et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003 -RRB-	39417
a 4-week delay	39417
Liu et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003	39433
Liu	39433
et al. , 1999 ; Jin et al. , 2002 ; Shumsky et al. , 2003	39437
et al. , 1999	39437
et al.	39437
1999	39445
Jin et al. , 2002	39451
Jin	39451
et al. , 2002	39455
et al.	39455
2002	39463
Shumsky et al. , 2003	39469
Shumsky	39469
et al. , 2003	39477
et al.	39477
2003	39485
the lesion-matrix-only animals	39503
independent use of their impaired forelimb -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	39552
independent use	39552
their impaired forelimb -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	39571
their impaired forelimb	39571
Liu	39596
et al. , 1999 ; Jin et al. , 2002	39600
et al.	39600
1999 ; Jin et al.	39608
1999	39608
Jin et al.	39614
Jin	39614
et al.	39618
2002	39626
spontaneous vertical exploration	39640
we	39674
horizontal rope	39686
test	39710
12 weeks	39715
transplantation	39730
Results	39747
NSFCs-engrafted rats	39769
better performance	39800
lesion-matrix-only -LRB- data not shown -RRB- , which was similar to our previous report -LRB- Xiao et al. , 2005 -RRB-	39824
lesion-matrix-only -LRB- data not shown -RRB-	39824
lesion-matrix-only	39824
data not shown	39844
data	39844
our previous report -LRB- Xiao et al. , 2005 -RRB-	39882
our previous report	39882
Xiao	39903
et al. , 2005	39908
et al.	39908
2005	39916
addition	39926
we	39936
the Basso , Beattie , Bresnahan -LRB- BBB -RRB- locomotor rating scale to evaluate functional recovery of the hind limb 12 weeks after transplantation	39954
the Basso , Beattie , Bresnahan -LRB- BBB -RRB- locomotor rating scale	39954
Basso , Beattie , Bresnahan -LRB- BBB -RRB-	39958
Basso , Beattie , Bresnahan	39958
BBB	39985
functional recovery of the hind limb 12 weeks	40025
functional recovery	40025
the hind limb 12 weeks	40048
the hind limb	40048
12 weeks	40062
transplantation	40077
BBB scores of right hind limb -LRB- ipsilateral to the lesion site -RRB- in the NSFCs-engrafted group	40103
BBB scores	40103
right hind limb -LRB- ipsilateral to the lesion site -RRB- in the NSFCs-engrafted group	40117
right hind limb -LRB- ipsilateral to the lesion site -RRB-	40117
right hind limb	40117
ipsilateral to the lesion site	40134
ipsilateral	40134
the lesion site	40149
the NSFCs-engrafted group	40169
those in the lesion-matrix-only -LRB- 16 ± 2.5 vs. 13.5 ± 3.1 , n = 16 , p < 0.05 -RRB-	40221
those	40221
the lesion-matrix-only -LRB- 16 ± 2.5 vs. 13.5 ± 3.1 , n = 16 , p < 0.05 -RRB-	40230
the lesion-matrix-only	40230
16 ± 2.5 vs. 13.5 ± 3.1 , n = 16 , p < 0.05	40254
16 ± 2.5 vs. 13.5 ± 3.1	40254
16 ± 2.5	40254
16	40254
2.5	40257
13.5 ± 3.1	40265
13.5 ±	40265
3.1	40270
n = 16	40275
n	40275
16	40277
p < 0.05	40281
p <	40281
p	40281
0.05	40283
we	40290
this behavioral improvement	40311
RST axonal regeneration	40342
the Results section -LRB- Fig. 3 -RRB-	40388
the Results section	40388
Fig. 3	40409
most of the regenerated RST axons	40418
most	40418
the regenerated RST axons	40426
the	40426
RST axons	40442
the distal cervical segments and a few	40468
the distal cervical segments	40468
a few	40501
the mid-thoracic segments	40515
no BDA-labeled axon	40546
the L1 -- S5 segments in NSFCs-engrafted rats	40582
the L1	40582
S5 segments in NSFCs-engrafted rats	40589
S5 segments	40589
NSFCs-engrafted rats	40604
our opinion	40629
one	40642
the functional recovery	40682
cellular transplantation	40712
clear and unambiguous evidence	40745
the conclusion of axonal regeneration	40785
the conclusion	40785
axonal regeneration	40803
Partial recovery of hind limb function in PCHX rat model	40824
Partial recovery	40824
hind limb function in PCHX rat model	40844
hind limb function	40844
PCHX rat model	40866
the collateral branches of other intact descending tracts in the distal segments	40917
the collateral branches	40917
other intact descending tracts in the distal segments	40944
other intact descending tracts	40944
the distal segments	40978
Functional recovery	40999
irreversible and reversible lesions of regenerated RST	41036
irreversible and reversible lesions	41036
regenerated RST	41075
Functional recovery	41091
RST axonal regeneration and reinnervation	41127
RST axonal regeneration	41127
reinnervation	41155
occurrences of forelimb dysfunction	41197
occurrences	41197
forelimb dysfunction	41212
irreversible and reversible lesions of RST	41239
irreversible and reversible lesions	41239
RST	41278
Recovery of forelimb usage	41283
Recovery	41283
forelimb usage	41295
an irreversible lesion of the regenerated RST axons following the right DLF at the C2 level	41335
an irreversible lesion	41335
the regenerated RST axons following the right DLF at the C2 level	41361
the	41361
RST axons following the right DLF at the C2 level	41377
RST axons	41377
the right DLF at the C2 level	41397
the right DLF	41397
the C2 level	41414
This procedure	41428
the regenerated RST axons and results in forelimb dysfunction	41461
the regenerated RST axons and results	41461
forelimb dysfunction	41502
regenerated RST axons	41530
recovery of forelimb posture and motor function	41575
recovery	41575
forelimb posture and motor function	41587
These results	41624
those described in previous studies with other engraftment procedures -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	41653
those	41653
previous studies	41672
other engraftment procedures -LRB- Liu et al. , 1999 ; Jin et al. , 2002 -RRB-	41694
other engraftment procedures	41694
Liu	41724
et al. , 1999 ; Jin et al. , 2002	41728
et al.	41728
1999 ; Jin et al.	41736
1999	41736
Jin et al.	41742
Jin	41742
et al.	41746
2002	41754
the irreversible surgical lesion	41773
reversible blockade of RN neurons by muscimol	41807
reversible blockade	41807
RN neurons by muscimol	41830
RN neurons	41830
muscimol	41844
more direct evidence	41862
the regenerated RST axons	41888
the	41888
RST axons	41904
the recovery of forelimb function	41928
the recovery	41928
forelimb function	41944
Muscimol	41963
gammaaminobutyric acid -LRB- GABA -RRB- agonist for inactivation experiments -LRB- Martin and Ghez , 1999 -RRB-	41993
gammaaminobutyric acid -LRB- GABA -RRB- agonist	41993
inactivation experiments -LRB- Martin and Ghez , 1999 -RRB-	42035
inactivation experiments	42035
Martin and Ghez	42061
1999	42078
It	42085
cells bodies where the GABA receptor is located , but not axons -LRB- Martin and Ghez , 1999 -RRB-	42110
cells bodies where the GABA receptor is located	42110
cells bodies	42110
the GABA receptor	42129
axons -LRB- Martin and Ghez , 1999 -RRB-	42167
axons	42167
Martin and Ghez	42174
1999	42191
Previous studies	42198
the distribution of GABA receptors	42233
the distribution	42233
GABA receptors	42253
the RN -LRB- Hironaka et al. , 1990 -RRB-	42271
the RN	42271
Hironaka	42279
et al. , 1990	42288
et al.	42288
1990	42296
Injection of muscimol into the RN	42303
Injection	42303
muscimol into the RN	42316
muscimol	42316
the RN	42330
reversible impairment	42363
an elbow tracking task of cats for several days -LRB- Martin et al. , 1993 -RRB-	42388
an elbow tracking task	42388
cats for several days -LRB- Martin et al. , 1993 -RRB-	42414
cats	42414
several days -LRB- Martin et al. , 1993 -RRB-	42423
several days	42423
Martin	42437
et al. , 1993	42444
et al.	42444
1993	42452
Injection of muscimol into the magnocellular portion of the RN	42459
Injection	42459
muscimol into the magnocellular portion of the RN	42472
muscimol	42472
the magnocellular portion of the RN	42486
the magnocellular portion	42486
the RN	42515
the comparison of posture and motor function of the contralateral forelimb	42527
the comparison	42527
posture and motor function of the contralateral forelimb	42545
posture and motor function	42545
the contralateral forelimb	42575
recovery possible	42627
Significant proximal and distal forelimb dysfunction relating to extension	42646
Significant proximal and distal forelimb dysfunction	42646
distal forelimb	42671
extension	42711
18	42735
24 h after injection	42738
24 h	42738
injection	42749
it	42796
48 h. Similar to the irreversible lesion	42824
48 h.	42824
the irreversible lesion	42841
the rostral DLF	42868
the injection of muscimol	42885
the injection	42885
muscimol	42902
no right forelimb usage	42923
limited use of both forelimbs indicating the pharmacological blockade	42951
limited use	42951
both forelimbs indicating the pharmacological blockade	42966
both forelimbs	42966
the pharmacological blockade	42992
RST neuronal activity	43049
These results	43072
repeated injections of muscimol	43114
repeated injections	43114
muscimol	43137
muscimol reactions	43153
pharmacological inactivation	43203
an effective tool in assessing functional recovery after spinal cord injury	43239
an effective tool	43239
functional recovery	43270
spinal cord injury	43296
We	43316
this	43327
the first time that pharmacologic inactivation has been correlated with recovery of forelimb function and regeneration of RST axons	43335
the first time	43335
pharmacologic inactivation	43355
recovery of forelimb function and regeneration of RST axons	43407
recovery	43407
forelimb function and regeneration	43419
RST axons	43457
conclusion	43471
the present studies	43483
neural progenitors from adult human ONe progenitors	43535
neural progenitors	43535
adult human ONe progenitors	43559
RST axonal regeneration and reinnervation	43599
RST axonal regeneration	43599
reinnervation	43627
functional recovery	43653
the acute SCI of rats	43683
the acute SCI	43683
rats	43700
NSFCs harvested from ONe	43706
NSFCs	43706
ONe	43727
a suitable source of adult neural progenitor cells which can be obtained with minimally invasive surgery	43739
a suitable source	43739
adult neural progenitor cells which can be obtained with minimally invasive surgery	43760
adult neural progenitor cells	43760
minimally invasive surgery	43817
the progenitor nature of these NSFCs	43852
the progenitor nature	43852
these NSFCs	43877
they	43890
either oligodendrocytes or neurons	43920
Marshall et al. , 2006	43956
Marshall	43956
et al.	43965
2006	43973
Adult human ONe progenitors	43980
a unique therapeutic potential for use in autologous grafting or transplantation aimed at repairing SCI and other neurodegenerative disorders	44017
a unique therapeutic potential	44017
use in autologous grafting or transplantation aimed at repairing SCI and other neurodegenerative disorders	44052
use	44052
autologous grafting or transplantation	44059
SCI and other neurodegenerative disorders	44117
SCI	44117
other neurodegenerative disorders	44125
